Hybrid Medical Analytics Inc

Today announced that its board of directors has named Selene Flores as its new president and chief executive officer

2012-01-23T18:26:00.000-08:00

Houston, Jan. 23, 2011 /PRNewswire/ -- GenNxeix, Inc. Today announced that its board of directors has named Selene Flores as its new president and chief executive officer. Selene, who will also become a member of its Board of Directors, starts at GenNxeix on January 24th.

"After an extensive and thorough search, we're delighted to have selected Flores as our new CEO," said GenNxeix company founder and board chairman Robert Graham Ph.D. "Flores is a terrific product executive who has also demonstrated exceptional business and leadership skills. She's a perfect fit to take GenNxeix into the future. We will leverage Flores' extensive background in customer-driven product strategy and delivery to ensure GenNxeix' strategic plan is focused and optimized for growth."

"Honored to be joining GenNxeix, an industry pioneer in Genomic science applications and services," Flores said. "While there's a lot of work to do, GenNxeix has incredible and unique assets upon which to build, including a very talented team. I'm excited about the opportunity to help lead GenNxeix on to the next great chapter in its success. "

Flores will be taking over from Rose Conrad, who has served as CEO since March 1999. Conrad, who has been an executive at GenNxeix since 1998,

GenNxeix creates innovative Genomic Biotech applications and services that make it easy for Cancer Patients to make intelligent decesions about chemotherapy. GenNxeix invented the GenNxeix Breast Cancer Toolkit aiming to support every Breast Cancer Patient, Clinical Trial, and Doctors Office Find corporate information at www.GenNxeix.com/

GenNxeix is a registered trademark of GenNxeix, Inc. All other trademarks, names of actual companies and products mentioned herein are the property of their respective owners.

Forward Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to the future success of GenNxeix. More information about potential risk factors that could affect business and financial results is included in the GenNxeix annual report on Form 10-K for the most recent year ended December 31, and its quarterly reports on Form 10-Q and, from time to time, in other reports filed by GenNxeix. Actual results may differ materially from estimates under different assumptions or conditions. GenNxeix assumes no obligation to update any forward-looking statements or information, which are in effect as of their respective dates.

SOURCE GenNxeix, Inc.

New Break in the Fight Against Breast Cancer

2012-01-23T16:33:00.000-08:00

Hybrid Pharmaceutical GenNxeix , the Genomics Biotech Engineering company, CEO Selene Flores gives us
New break in the fight against breast cancer is a science. From MD Anderson Houston TX,

New break in the fight against breast cancer, is a science term called autophagy. Autophagy is a biological process involving self-digestion of breast cellular material when breast cells are
deprived of nutrients or in stress. In most cases, Autophagy acts as a breast cell survival mechanism protecting breast cells from different types of stress. Autophagy has been shown to play roles in normal physiological processes including energy metabolism, organelle turnover, growth regulation, and aging. Impaired breast autophagy leads to cancer. Autophagy has also been implicated in the cellular response to anti-breast cancer therapies.

Identification and characterization of regulators of autophagy in patient samples, breast cancer cell line and mouse models is a area of research that GenNxHybrid GenNxeix scientist in Galveston Texas focus on.

GenNxeix functional genomics, and proteomics approaches to identify and characterize factors required for breast cell death and autophagy in the clinical breast cancer samples. GenNxeix pharmacodynamics and pharmacokinetic effect on autophagy in anti-cancer therapy. Alteration of autophagy in endocrine therapy, chemotherapy and/or irradiation therapy is the nature tested. Evidence suggests that autophagy acts as a tumour suppressor and should be stimulated to decrease the incidence of cancer in breast cells. Analysing the reletionship between tumour suppression and autophagy genes in breast cancer.

Autophagy is an evolutionarily conserved mechanism of cellular self-digestion in which proteins and organelles are degraded through delivery to lysosomes. GenNxeix notice defects in this process is implicated in breast cancer. To understand autophagy, we performed a functional screen in search of microRNAs (miRNAs), which regulate the autophagic flux in breast cancer cells. As a result GenNxeix Scientist identified the tumour suppressive miRNA, miR-101, as a potent inhibitor of basal, etoposide- and rapamycin-induced autophagy. GenNxeix Scienyidt uses transcriptome to identified three novel miR-101 targets, ”STMN1″, ”RAB5A” and ”ATG4D”. where siRNA-depletion of these genes phenocopied the effect of miR-101overexpression, to demonstrating the genes importance in autophagy regulation. Importantly, overexpression of ”STMN1″could partially rescue cells from miR-101-mediated inhibition of autophagy. As a Result miR-101-mediated inhibition of autophagy will sensitize breast cancer cells to 4-hydroxytamoxifen mediated cell death. This is a classic case where genomics is here to stay.

The Breast Cancer Cure Blueprint 2012 Report Card.

2011-12-28T00:59:00.001-08:00

Hybrid Pharmaceutical, the Genomics Biotech Engineering company, CEO Rose Conrad Ph.D. gives us
The Breast Cancer Cure Blueprint 2012 Report Card. From MD Anderson Galveston TX, Campus Business Wire

Hybrid GenNxeix Breast Cancer Researchers and Scientist are ahead of the curve with several new technologies based on Nanoparticles and Semi Conductors Namely Genomics and treatments.
The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.

The result is that the ability to determine Targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data.

The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3000.00.
The lower cost, along with increasing speed, has led to a huge increase in how much breast Cancer sequencing data is being produced.

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid GenNxeix Researchers Say that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. The heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
Hybrid GenNxeix understands that Hyperthermia gold nanoshell Targeted breast cancer genomics at 40 for high risk women will reduce breast cancer at 60 years of Age. Training Genomics Counselor and Storing DNA Analysis in the cloud will allow Hybrid GenNxeix to say that Chemotherapy will help their breast cancer outcome or if Chemotheraphy and Hyperthermia will extend their life.

Texas is Doing Great Things to Help in The Creation of a Blueprint for a Breast Cancer Cure

2011-12-01T10:00:00.000-08:00

Houston, TX – December 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Media Reporting From The Texas Workforce Commission Meeting Houston TX Galleria

Texas is doing great things to help in The Creation of a Blueprint for a Breast Cancer Cure. The University of Texas M.D. Anderson Cancer Center and The Texas
Workforce Commission Skills Development Fund are two Texas organizations that has the synergy to create a 100,00 Jobs according to Rose Conrad CEO of Hybrid GenNxeix when incorporating Nanoparticles and Semiconductor to the Drug Discovery Process.
Just this Week University of Texas M.D. Anderson Cancer Center is stocking up on scientists and plunging into the business of drug development, a major upgrade to areas that have lagged considerably behind the institution's clinical-care reputation.
The creation of the Institute for Applied Cancer Science, an effort aimed atconverting basic discoveries into new cancer therapies. The institute will be staffed by 28 scientists newly recruited from a similar initiative at the Harvard-affiliated Dana Farber Cancer Center. That initiative was co-founded and headed by Dr. Ronald DePinho, M.D. Anderson's new president.
"This will allow us to exploit opportunities provided by recent transformative technological and scientific advances and launch a biotech industry in Houston," said DePinho, who succeeded Dr. John Mendelsohn Sept. 1. "It should improve an appallingly low rate of success in the current cancer drug pipeline.".
The Texas Workforce Commission Skills Development Fund is Texas' premier job–training program providing training dollars for Texas businesses and workers. Administered by the Texas Workforce Commission, success is achieved through collaboration among businesses, public Community and Technical colleges, Local Workforce Development Boards and economic development partners.
For the next two fiscal years (September 1, 2011 – August 31, 2013), TWC has $48 million in Skills Development Funds to support high quality, customized job training projects across the state. Grants for a single business may be limited to $500,000.
How does it work?
A business, consortium of businesses, or trade union identifies a training need, and then partners with a public Community or Technical college to fill its specific needs. Businesses work with college partners to submit proposals, develop curricula and conduct training. The Skills Development Fund pays for the training, the college administers the grant, and businesses create new jobs and improve the skills of their current workers. How The Synergy would work:

GenNxeix scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs

Hybrid GenNxeix Genomics Science Black Tie Ball

2011-11-30T01:32:00.000-08:00

HOUSTON, Jan 5/PRNewswire/ — Hybrid Medical is one of the leading supporters of Genomics Science Black Tie Ball to take place April 14 at the Hotel ZA ZA in Houston. Proceeds from the event will support Houston Symphony and American Cancer Soceity, to initiate the development and deployment of promising new Genomics Science and therapies to improve and save patient lives. The celebrity chairperson of The Genomics Science Black Tie Ball is Congress Women Shelia Jackson Lee.
“As a Biotech Engineering company, Hybrid Medical is honored to support The Genomics Science Black Tie Ball ,” says Robert Graham, Executive Vice President of Hybrid Medical North America. “It is only through the medical community and philanthropic outreach that we can complete our mission, which is putting into the hands of healthcare professionals the tools they need to treat breast cancer and to improve, prolong and save patient lives.”

The first and only freestanding Genomics Biotech Engineering center of its kind in Houston, The Hybrid Medical GenNxeix, is hosting the event, as well as serving as a major sponsor Lilly.

“Genomics Science Black Tie Ball was put together with the same principles for why we started Hybrid Medical on the most humanistic level,” says Rose Conrad., the Center’s Founder and CEO. “It is about giving back to people and the community, and bringing genomics cancer care to the next level. It is in harmony with Hybrid Medical’s philosophy, which emphasizes caring for the whole person, not just treating their disease. The most fundamental understanding of the preciousness of life is what has driven us to pursue our dream to help people with cancer–to help them live fuller lives while under our care and ideally once their disease is defeated.”

Houston Press

PERFORMANCES

The fundraiser will feature a musical performance by Kristine Mills, www.kristinemillsmusic.com Houston's "bold, blonde entertainer outta the old school" and the Tommy "TJ" James Trio. An award-winning songwriter, Kristine will show off her skills and during her gala performance. Ms. Mills and her band will record live a song she will write about her friend's battle with breast cancer. Krisitne celebrates over two decades of an accomplished music career, and continues to impress international audiences, music authorities and the press with her songwriting, extensive repertoire, and polished, sophisticated vocals. She is also the winner of the Houston Press Music 2009 “Best Female Vocalist,” Award.

“Every once in a while you see a live performance so good it sends shivers up your spine. Be ready for some shiver action when jazz singer Kristine Mills steps onstage.” Houston Press

Kristine will make her New York City debut on February 17th, 2012 at the legendary Metropolitan Room with Mr. Tommy “TJ” James, the pianist, conductor, and arranger of the Duke Ellington Orchestra. Over the years Tommy has performed, recorded and arranged for an eclectic group of artistsin many musical genres including: Lionel Hampton, Eartha Kitt, MaureenMcGovern, Cleo Laine/John Dankworth, Nell Carter, The Spinners, and the Temptations. Kristine met Mr. James when she performed as guest vocalist withthe Duke Ellington Orchestra in the 2007 Brazilian International Jazz Festival tour in Brazil. She also performed with the Duke Ellington “small” Orchestra for the 50th Jubilee Celebration of the Mies van der Rohe Society in Chicago.

Kristine and Tommy led Kristine’s Houston-based jazz combo in a 2008 benefit concert in honor of the late, great Rocky White veteran drummer for the Duke Ellington Orchestra who lost his battle with cancer in June 2008. Ms. Mills performed for the 2011 American Cancer Society Palm Beach Chapter Gala for Mr. Donald Trump and was featured in three showcases for the 2010 Miami Music Festival. August 2009 Kristine headlined the Brazilian International Jazz Festival with her Rio-based, bossanovafied band to sold-out theaters in Recife, Rio de Janeiro and Belo Horizonte.

About Hybrid Medical

Hybrid Medical is a genomics science company pioneering significant innovations and clinical solutions for treating breast cancer . The company develops sophisticated, state-of-the-art tools and treatment planning systems for genomics science therapy, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers , Hybrids aims to improve, prolong and even save patient lives, making the future possible.

Today, Hybrid solutions in oncology and neurosurgery used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Hybrid Medical Group.

Hybrid Medical

Robert Graham Reports Ny Times Ferrari Club Of Houston Says President Obama We Want To Pay Our Share

2011-11-22T13:37:00.000-08:00

Robert Graham Reports Ny Times Ferrari Club Of Houston Says President Obama We Want To Pay Our Share:

Houston Highland Villiage

The New Leading Technology To Cure Breast Cancer is Here Nanoparticles and Semiconductor

2011-11-16T17:58:00.000-08:00

Houston, TX – November 17, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Medical Media

The New Leading Technology To Cure Breast Cancer is Here according to Rose Conrad Ph.D. CEO of Hybrid GenNxeix Inc Nanoparticles and Semi Conductors

Hybrid GenNxeix Conrad explains Quantum dots (QDs), also known as semiconducting nanoparticles, are promising zero‐dimensional advanced materials because of their nanoscale size and because they can be engineered to suit particular applications such as nonlinear optical devices (NLO), electro‐optical devices, and computing applications. QDs can be joined to polymers in order to produce nanocomposites which can be considered a scientific revolution of the 21st century. One of the fastest moving and most exciting interfaces of nanotechnology is the use of QDs in medicine, cell and molecular biology. Recent advances in nanomaterials have produced a new class of markers and probes by conjugating semiconductor QDs with biomolecules that have affinities for binding with selected biological structures. The nanoscale of QDs ensures that they do not scatter light at visible or longer wavelengths, which is important in order to minimize optical losses in practical applications. Moreover, at this scale, quantum confinement and surface effects become very important and therefore manipulation of the dot diameter or modification of its surface allows the properties of the dot to be controlled. Quantum confinement affects the absorption and emission of photons from the dot. Thus, the absorption edge of a material can be tuned by control of the particle size. Nanocomposite systems for nanomedicine and bioengineering applications

Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer.

GenNxeix scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs

There is A Tool That Calculates A Woman Risk of Developing Breast Cancer Within The Next Five Years

2011-11-03T09:33:00.000-07:00

Houston, TX – November 03, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Medical Media:

President Obama IS Women with Breast Cancer Being Cheated

Your Breast Cancer diagnosis is just average number. Yes a Gail number

92% Of Oncologist use something called a Gail Model for Breast Cancer Diagnosis & Treatment. Genomics is 72 % more effective than the Gail Model
Women What Are We doing About a Cure for Breast Cancer Today. Genomic is The Next Generation to The Gail Model
Background:

The Breast Cancer Risk Assessment Tool (the Gail model) was designed by researchers at the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project as a tool for health care providers. The tool calculates a woman's risk of developing breast cancer within the next five years and within her lifetime (up to age 90). It takes into account seven key risk factors for breast cancer.
• Age
• Age at first period
• Age at the time of the birth of her first child (or has not given birth)
• Family history of breast cancer (mother, sister or daughter)
• Number of past breast biopsies
• Number of breast biopsies showing atypical hyperplasia
• Race/ethnicity
Hybrid GenNxeix Researchers notice that the Breast Cancer Risk Assessment Tool does not calculate individual breast cancer risk, but rather the average risk for a group of women with similar risk factors. Thus, it is not clear what this risk means for any one woman. Say the model gives you a five-year risk of 1.7 percent. This means the tool estimates that 1.7 percent of women who have risk factors similar to your own will develop breast cancer over the next five years.
Women who have a five-year risk of 1.67 percent or higher (of the risk of an average 60-year-old woman) are classified as "high-risk". This score (a five-year risk of 1.67 percent or higher) is the cut-off for the FDA guidelines on tamoxifen and raloxifene use for breast cancer risk reduction.
Targeted therapies are transforming the way people treat cancer. These carefully designed drugs have already begun to make Genomic personalized medicine a reality and will continue to help doctors tailor cancer treatment based on the characteristics of each individual's cancer. It is important that health care professionals become familiar with the concept of targeted therapies so they can communicate with their patients about these new approaches and help patients make better-informed treatment decisions.
Treatment for breast cancer depends on the stage of the disease, but often includes surgery, radiation therapy, and chemotherapy. Some targeted therapies, including antihormone therapies and Herceptin® (trastuzumab), have also become part of standard treatment for breast cancer when a patient's tumor expresses the targets of these drugs. Preclinical experiments and clinical trials are currently underway to evaluate additional targeted therapies a

Hybrid GenNxeix Chief Science Officer says 75% of breast tumors rely on estrogen. These tumors are referred to as "estrogen dependent." Tumors that do not rely on estrogen for growth are called "estrogen independent."

The epidermal growth factor receptor family consists of four cell surface receptors: EGF receptor, also called HER1; HER2/neu; HER3; and HER4. Binding of specific growth factors, or ligands, to three of these receptors causes them to interact, or dimerize, either with a receptor of the same type or with another family member. HER2 is called an "orphan receptor" because it does not interact directly with any ligand. Instead, it dimerizes with ligand-bound EGF receptor, HER3, or HER4.

Hybrid GenNxeix Chief Science Officer says 20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.
science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.

Hybrid Pharmaceutical, The Genomics Biotech Engineering Company, announced Barron Graham’s –Join Hybrid GenNxeix Inc as Chief Information Officer

2011-10-30T04:17:00.000-07:00

Houston, TX – November 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceutical, the Genomics Biotech Engineering company, today announced that Barron Graham’s – Graham is to join Hybrid GenNxeix Inc. (GenNxeix) as a Biotech Consulting Partner effective November 1, 2011. Barron will work directly with the Vice President of Worldwide Marketing in developing strategic marketing, branding, communications and sales initiatives for Hybrid GenNxeix ®. Mr. Graham bring more than 28years of expertise in brand management, business planning, advertising, digital, integrated communications, direct marketing, promotions, research and sales & marketing.

Barron brings a breath of experience and strong track record of leadership in successfully building brands and pioneering new markets,” said Rose Conrad Ph.D., Chief Executive Officer of Hybrid Pharmaceutical.
“His years of experience in developing go-to-market strategies, his intelligence and his excitement to become part of Hybrid GenNxeix is evident that Barron’s direction and steward of the GenNxeix brand will help to strengthen and solidify our market leadership position,” she said.

Hybrid GenNxeix a new subsidiary of Hybrid Pharma, is committed to being the world’s premiere Medical Informatics and Medical Services Companies. As a leader in genomic trials, healthcare IT, scientist electronic GenNxeix, development and manufacturing of biologics, the company offers a suite of products and services. Products and services include DNA paternity testing, Genomics analysis and testing, BioGenetic research and samples and Regenerative medicine.

As an entrepreneur for more than 28 years, Barron Graham’s unique qualifications in Business Establishment, Business Development and Marketing makes him highly capable and much sought after in the business world. His experience and expertise came from across section of industries namely: Real Estate, Investment Banking, Telecoms Retail, Business Financing, Insurance, Merchant Services, Network Marketing and Business Establishment & Development. In which he is personally starting more than 100 companies in several countries.

This press release contains forward-looking statements, including statements relating to the expected demand for Hybrid Pharma's products and services, statements regarding Hybrid Pharma’s growth and market opportunities, and statements relating to Hybrid Pharma’s ability to meet the needs of distributed organizations. These forward-looking statements involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Hybrid Pharma reserves the right to modify future product plans at any time.
About Hybrid Pharma

Hybrid Pharma is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services is available at GenNxeix.

“As you look around, you’ll see that medicine has changed dramatically. There is a huge Genomic shift occurring. The Genomicst has completely redefined the world’s economy and has created evidence base Medicine. If you are in medicine today and you are not using Genomics Science o, you will be left behind.”

20% Of Breast Cancers IS HER2 over-expressed. HER2 Gene Amplified Has A 82% Chance of Relapses

2011-10-09T13:39:00.000-07:00

Robert Graham and Hybrid Medical Media Reporting from University of Texas Houston October, 2011-------

20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.
science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.

The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect
the Her2 gene by using Semiconductor Sequencing. A example of
this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA ohttp://www.blogger.com/img/blank.gifr RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.

Where do we really come from And how can this information help solve Breast Cancer

2011-09-19T13:39:00.000-07:00

Robert Graham and Hybrid Medical Media Reporting from University of Texas Galveston September 6, 2011-------
Where do we really come from And how can this information help solve Breast Cancer
Where do we really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Brhttp://www.blogger.com/img/blank.gifeast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2

The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.

The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect
the Her2 gene by using Semiconductor Sequencing. A example of
this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA ohttp://www.blogger.com/img/blank.gifr RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.

Hybrid Medical Media Covers this years Cadillac Simon Fashion Show

2011-09-11T19:27:00.000-07:00

Robert Graham and Hybrid Medical Media Reporting from Houston Galleria Simon Fashion Show September 8, 2011

Why Hybrid GenConnect opened a Office in Houston
One Reason is that Houston has grown in Culture and Style
Hybrid Medical Media Cover this years Cadillac Simon Fashion Show.

Cadillac has been part of the Simon Fashion
NOW series since its appearance in Houston.
With artful design and precision performance,
Cadillac is a celebration of spring fashion trends.

As a part of this year’s fashion extravaganza,
Cadillac is at the forefront of art and design with
a new interactive style stop.

What is Better Than a Mammogram and can Help The Obama Administration Create 4 Million Jobs

2011-09-06T09:34:00.000-07:00

What is Better Than a Mammogram and can Help The Obama Administration Create 4 Million Jobs
Robert Graham and Hybrid Medical Media Reporting from Rice University September 6, 2011

What is Genomics? Genomics is a new and fast expanding area of biology encompassing high throughput or large scale experimentation at the whole genome level, and the organization, analysis and interpretation of the huge amount of data emerging from genome projects. Major new technologies have evolved recently that enable experimentation at the whole genome level, and more novel technologies are currently being developed. This volume describes in detail the new technology necessary to study the entire genome in a holistic manner and all the high throughput and large-scale experimental methodologies currently being used in genomic science. In addition the authors describe the progress of the newest technologies that are currently being developed. Written by experts in the field, this concise yet informative volume covers all aspects of technology pertaining to genomic studies. It is an essential book for anyone involved in genomic science.

Breast Cancer patients can aligning environmental science with regulation, Genomics in Regulatory Ecotoxicology: Applications and Challenges presents the first in-depth set of recommendations published in the open literature focused specifically on how genomics data could be used in regulatory ecotoxicology. The book develops a conceptual framework of how genomics data can most effectively impact current approaches for ecological risk assessments. It also identifies biomarkers of exposure and effects for both lab and field monitoring studies and provides a basis for the extrapolation of chemical effects across species. It explores exactly how data generated from new genomics technologies might impact or benefit risk assessment. Features: Identifies biomarkers of exposure and effects for use in both lab and field studies, Provides a basis for the extrapolation of chemical effects across species, Describes current and planned applications of genomic technologies to screening assays for use in ecotoxicology decision-making, including risk assessment, Focuses on the development and application of genomics to tiered testing, including how genomics may be used to support streamlining of current chemical testing programs, Highlights the application of genomic technologies to complex mixtures of contaminants in the environment, such as sites requiring remediation.
Breast Cancer Genomics in Regulatory Ecotoxicology: Applications and Challenges is one of many SETAC publications that offer timely, innovative, and critically reviewed perspectives on current topics relating to broad environmental toxicology and chemistry issues. SETAC assumes an active leadership in the development of educational programs and publishes the peer-reviewed, international journals Environmental Toxicology and Chemistry and Integrated Environmental Assessment and Management.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Hybrid GenConnect will Reduce Breast Cancer by 5 percentage points by 2014

Personalized Medicine in The Black community -Message to Martin Luther King Jr. Foundation

2011-08-25T10:01:00.000-07:00

August 28th, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

The State of Genomics and Personalized Medicine in The Black community -Message to Martin Luther King Jr. Foundation

Public Health Genomics (PHG) at the National Cancer Institute promotes the integration of genomics and personalized medicine into public health cancer research, policy, and control to reduce the burden of cancer in the United States and around the world.

Hybrid GenConnect Purpose in Genomic Science is to Draw from Organizational Theory and existing body of work about science. Hybrid seeks to operationalize a Model to represent empirical evidence that draws on Quanative mapping of Breast
Cancer

18% of Black Women get Breast Cancer to 7% of White Women, what can we do to reduce the Breast Cancer rate in the Black Community. GenConnect located in Houston at the University of Texas Medical Center research area. Suggested that more research be used using real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. A long with Nanoparticles which has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer for Black Women.
GenConnect offers both absolute and relative quantitation using calibration curves and a choice of normalization strategies. Full validation to ICH guidelines is available to support the analysis of transcript biomarkers as part of a clinical trial.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Hybrid GenConnect will Reduce Breast Cancer by 5 percentage points by 2014

Genomics and Gastric bypass surgery -- decreases the incidence of Breast Cancer by 80%

2011-07-14T09:12:00.000-07:00

July 14, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Genomics and Gastric bypass surgery -- decreases the incidence of Breast Cancer by 80%

Gastric bypass procedures (GBP) is operations that divides the stomach into a small upper pouch and a much larger lower "remnant" pouch and then re-arranges the small intestine to allow both pouches to stay connected to it. Surgeons have developed several different ways to reconnect the intestine, thus leading to several different GBP names. Any GBP leads to a marked reduction in the functional volume of the stomach, accompanied by an altered physiological and physical response to food
Hybrid GenConnect Inc estimated 908,000 people in the U.S. had gastric bypass, gastric banding , or some other form of bariatric.

Candidates for bariatric surgery include those who are morbidly obese, which for most people means being 100 or more pounds overweight or having a body mass index (BMI) of 40 or more.

A 5-foot, 8 -inch person who weighs 250 or more would be considered morbidly obese, as would someone who is 6 feet tall and weighs at least 295 pounds.

Hybrid GenConnect Inc and others studied 900,000 adults followed for 16 years, Calle, et al, found the death rate from cancer was increased by 52 percent in men and 62 percent in women when the initial BMI was 40 or more. Cancers of the esophagus, colon and rectum, liver, gall bladder, pancreas, kidney, non-Hodgkins lymphoma and multiple myeloma were increased in both men and women. Stomach and prostate cancer was increased in men. Breast, uterus, cervix and ovary cancer were increased in women. They estimated, on the basis of this study, that overweight and obesity could account for 14 percent of all cancer deaths in the United States in men and 20 percent in women.
The newly reported study included 1,035 morbidly obese patients who underwent bariatric surgery between 1986 and 2002 and 5,746 patients matched for age, gender, and duration of morbid obesity who did not have surgery.

During five years of follow-up, 21 (2%) surgically treated patients were diagnosed with cancer, compared to 487 (8.5%) of nonsurgically treated patients.

The bariatric surgery patients had an 85% lower incidence of breast cancer, a 70% lower incidence of colon and pancreatic cancer, a 50% lower incidence of non-Hodgkin's lymphoma, and a 60% lower incidence of skin cancer
Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find P53,P63,BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid GenConnect breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.

Black Women #1 Concern The hTERT Gene for Breast Cancer

2011-06-22T15:11:00.000-07:00

June 22, 2011 By Robert Graham Reporting Park Plaza Medical Center in Houston Texas is looking at the hTERT Gene for Breast Cancer -----< Business--Wire>

Hybrid GenConnect Genomics Project at its new location at Park Plaza Medical Center in Houston Texas is looking at the hTERT Gene for Breast Cancer

hTERT (human telomerase reverse transcriptase) gene is the rate-limiting determinant of telomerase reactivation. The GenConnect study aims to quantitatively measure the expression of hTERT mRNA in human breast cancer, adjacent non-cancerous tissue (ANCT) and benign breast lesions, examine the association between hTERT and the clinicopathological characteristics of the cancer specimens and to explore the relationship between c-Myc and hTERT expressions. GenConnect extracted RNA from 49 breast carcinomas, 46 matched ANCT, and eight fibroadenomas. hTERT and c-Myc mRNA expressions were estimated by reverse transcriptase-PCR (RT-PCR) and Taqman methodology.

Hybrid GenConnect Genomics R&D shows that Breast cancer is the second leading cause of cancer death among American women. African American (AA) women are more likely to die from breast cancer than Caucasian (CAU) women revealing a clear disparity between AA women and women of other ethnicities. Genetic Data collected by Hybrid GenConnect and others reveal that although AA women show a lower incidence of breast cancer than CAU women, AA women tend to have larger, more aggressive tumors, and have a lower 5-year survival rate than their CAU, Hispanic, Asian and Native American counterparts. Importantly, AA women are more likely to die from breast cancer than any other ethnic group. While socio-economic, cultural and environmental factors are thought to contribute to these disparities, little is known as to whether biological differences may exist between CAU and AA women with breast cancer. To determine whether biological factors contribute to differential cellular responses in AA and CAU women, triple-negative breast cancer cells from AA and CAU women were cultured and treated with dietary bioactive compounds (−)- epigallocatechin-3-gallate (EGCG) and sulforaphane (SFN), both of which are known to actively repress breast cancer. Preliminary findings reveal differential RNA expression of the human telomerase reverse transcriptase gene (hTERT) in AA and CAU cells. Additionally, AA cells showed differences in responsiveness to ECGG and SFN treatments when compared to CAU cells. These results support
the hypothesis that biological differences may contribute to the disparity among AA and CAU women with breast cancer.

Given Treatment of A431 cells with green tea polyphenols and its components, epigallocatechin-3-gallate, epigallocatechin, and epicatechin-3-gallate, resulted in the formation of internucleosomal DNA fragments, characteristic of apoptosis. Treatment with epigallocatechin- 3-gallate also resulted in apoptosis in HaCaT, L5178Y, and DU145 cells, but not in NHEK. Confocal microscopy and flow cytometry confirmed the findings. The DNA cell cycle analysis showed that in A431 cells, epigallocatechin- 3-gallate treatment resulted in arrest in the G0−G1 phase of the cell cycle and a dose-dependent apoptosis. Conclusions: Green tea may protect against cancer by causing cell cycle arrest and inducing apoptosis. It needs to be evaluated in human trials.
Given Treatment sulforaphane, a natural component of broccoli and other brassica vegetables, reduces the growth of breast cancer stem cells and impairs their viability. The effects of sulforaphane on breast cancer stem cells in the laboratory were evaluated using various methods. Sulforaphane was found to reduce the stem cell population (as measured by a stem cell marker) by 65% to 80% in human breast cancer cells. In an additional experiment, mice were implanted with breast cancer xenografts and the tumors were treated directly with sulforaphane. The impact of the treatment was assessed in part by measuring tumor growth upon cell reimplantation into a second group of mice. Daily injection with 50 mg/kg sulforaphane for two weeks was found to reduce the number of stem cells by more than 50% in the xenograft tumors. Sulforaphane's ability to eliminate breast cancer stem cells appeared to prevent tumor growth after the reimplantation of primary tumor cells into the second group of mice. The authors conclude that sulforaphane inhibits breast cancer stem cells and that the findings warrant further clinical evaluation.

Breast Cancer Survivors Families Epidemiology & Genomics Can Stop Cancer in its Tracks

2011-06-14T08:32:00.000-07:00

June 14, 2011 By Robert Graham Reporting from University of Texas Medical Center Houston -----< Business--Wire>

Breast Cancer Survivors Families Epidemiology & Genomics can Stop Cancer in its Tracks

Epidemiology: The study of the patterns, causes, and control of disease in groups of people.
Genomics: The study of the complete genetic material, including genes and their functions, of an organism.

Cancer epidemiology seeks to understand the biological, environmental and social risk factors of cancer with the goal of guiding efforts at prevention and

treatment. Examples of cancer research by Hybrid GenConnect researchers includes evaluation of the efficacy of chemoprevention to prevent secondary tumors, the association between racial disparities in breast cancer survival, the relationship between insulin resistance and breast cancer incidence, and the identification of genetic cancer susceptibility risk factors
Although genetic influences on breast cancer risk have been recognized for many years, high-throughput genotyping involving genome-wide association studies has transformed research on the etiology of cancer and many other diseases. This technological breakthrough and the agnostic search for signals have opened up avenues for research that otherwise would have remained hidden for years. For instance, we may not know why a variant in a "gene desert" (a stretch of DNA devoid of protein-encoding genes) is consistently associated with risks of breast, prostate, and several other cancers, but we must infer that an important model of genes and cancer induction needs major revision
Hybrid GenConnect Inc Genetic research experts within the Breast Cancer Division are investigating the role of genes in such diseases as Alzheimer’s disease, cardiovascular disease, diabetes, hypertension, obesity, respiratory diseases and vision disorders. Understanding the genetics of these diseases involves locating and characterizing the underlying genes, characterizing the extent and utility of DNA variation within and among populations, determining how patterns of DNA variation evolved in time and space, and establishing the impact of gene variation on the health of individuals, families and populations. Hybrid researchers are also responsible for developing computational and bioinformatic approaches and resources for investigating the genetic etiology of disease.
Hybrid GenConnect Research in Genomic Epidemiology (CHARGE), which is led by a team at Park Plaza Hospital, hope that pooling their combined resources will help speed the process of defining all the genetic factors involved in Breast Cancer. “Our first efforts will be to bring together all the data from the different groups so that they can be analyzed,” for Drug Safety/Epidemiology.
The new biorepository facility offers a wide range of storage options, including automated carousel controlled-room temperature storage at 15oC to 27oC, bulk sample storage at 15oC to 27oC, walk-in cold sample storage -20oC to 5oC, ultra-low temperature storage -70C to -80C, and -190oC vapor phase liquid nitrogen. In addition, Hybrid GenConnect maintains FDA 21 CFR Part 11 validated technology systems and adheres to U.S. Food and Drug Administration regulations, as well as U.S. Department of Transportation and International Air Transport Association guidelines.
About Hybrid GenConnect Inc,.
For 23 years, Hybrid Medical eNotebook Inc Core Competency are Biotech Engineering, Software Engineers, and Enterprise Networking. At Hybrid Medical we pride ourselves on our Boutique Relationship with our Private Sector and Public Sector Clients. This methodology allows us to be able to offer our Clients “End to End” Solutions to their Enterprise Services. We have done extensive Research in Service Oriented Architecture (S.O.A) and Enterprise Service Bus (ESB) and we feel that our Strategies and your Strategies create valuable Synergies. Let's investigate the Possibilities for Synergies between our Company and yours.
HMA Inc we provide Network Services Contracts that include: design, installation and management of wide area networks and local area networks; enterprise server services that include anti-virus and content filters; BlackBerry support; patch support; technical helpdesk support including network hardware and software maintenance; desktop hardware/software installation and integration; application development; systems integration; Java/Oracle and legacy database development and maintenance; and citywide closed-circuit television services.>
HMA Inc comprehensive data protection strategy can save your company time. Our Process of backing up files, applications, databases, email and networked devicesis protected to ensure business continuity and compliance. When your business matures and grows, the volume of data increases and newer and more complex data retention requirements are introduced you are covered by hmnotebook.com Cloud Data Center (MCDC)™

Hybrid GenConnect Expands U.S. Operations with Opening of New Biorepository Facility

2011-05-31T08:27:00.000-07:00

May 31, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----<

Hybrid GenConnect Expands U.S. Operations with Opening of New Biorepository Facility

Houston (May 26, 2011) – Hybrid GenConnect, the premier global provider of comprehensive sample management solutions, announced today that it has opened its new state-of-the-art biorepository facility in Houston. The 4,000-square-foot facility is part of the company’s strategic growth plan, and represents a Major investment by Hybrid GenConnect.
Strategically placed near the second largest Cities in the United States, the new facility is dedicated to the preparation, storage and cold-chain transport of human biological samples for a wide variety of customers, including academic centers, contract research organizations, donor programs and biotechnology companies. Within the facility, Hybrid GenConnect is continuing to employ a growing number of sample management experts, making it one of the largest and mohttp://www.blogger.com/img/blank.gifst technology-driven biorepositories in the world.
“Hybrid GenConnect is committed to its investment in comprehensive sample management solutions, and this new facility provides the company with the infrastructure needed to support our continued growth and services expansion,” said Rose Conrad, CEO of Hybrid GenConnect.
The facility expansion has provided Hybrid GenConnect the ability to offer sample preparation services, including automated liquid handling technology to ensure the accuracy and precision needed for high-throughput DNA and RNA extraction and verification.
The integration of these services allows Hybrid GenConnect to provide customers with a sample renewal and extension process to maximize their samples for comprehensive research and development activities. Once samples are processed, aliquots of blood and/or DNA products can be retrieved and scheduled for transport to research testing sites through the company’s proprietary tracking and inventory management system, GenTrack®. This process ensures samples are removed, transported, processed and replaced to storage in a compliant, consistent and efficient fashion.
“The future of drug discovery is in personalized medicine and genomic-based therapies, which will require an ability to store and analyze large quantities of tissue and blood samples,” added Conrad. “As this trend continues, an increasing amount of pharma and biotech companies rely on our expertise in comprehensive sample management to ensure their valuable biological samples are managed in optimal conditions and not jeopardized by pre-analytical variabhttp://www.blogger.com/img/blank.gifles that can have a negative impact on sample integrity.”
The new biorepository facility offers a wide range of storage options, including automated carousel controlled-room temperature storage at 15oC to 27oC, bulk sample storage at 15oC to 27oC, walk-in cold sample storage -20oC to 5oC, ultra-low temperature storage -70C to -80C, and -190oC vapor phase liquid nitrogen. In addition, Hybrid GenConnect maintains FDA 21 CFR Part 11 validated technology systems and adheres to U.S. Food and Drug Administration regulations, as well as U.S. Department of Transportation and International Air Transport Association guidelines.
About Hybrid GenConnect Inc,.
For 23 years, Hybrid Medical eNotebook Inc Core Competency are Biotech Engineering, Software Engineers, and Enterprise Networking. At Hybrid Medical we pride ourselves on our Boutique Relationship with our Private Sector and Public Sector Clients. This methodology allows us to be able to offer our Clients “End to End” Solutions to their Enterprise Services. We have done extensive Research in Service Oriented Architecture (S.O.A) and Enterprise Service Bus (ESB) and we feel that our Strategies and your Strategies create valuable Synergies. Let's investigate the Possibilities for Synergies between our Company and yours.
HMA Inc we provide Network Services Contracts that include: design, installation and management of wide area networks and local area networks; enterprise server services that include anti-virus and content filters; BlackBerry support; patch support; technical helpdesk support including network hardware and software maintenance; desktop hardware/software installation and integration; application development; systems integration; Java/Oracle and legacy database development and maintenance; and citywide closed-circuit television services.>
HMA Inc comprehensive data protection strategy can save your company time. Our Process of backing up files, applications, databases, email and networked devicesis protected to ensure business continuity and compliance. When your business matures and grows, the volume of data increases and newer and more complex data retention requirements are introduced you are covered by hmnotebook.com Cloud Data Center (MCDC)™

Certify Electronic Health Records in Texas is in good hands

2011-05-20T08:41:00.000-07:00

May 20, 2011 By Robert Graham --Houston Grand Hyatt ----Texas Medical Association Conference

Certify electronic health records in Texas is in good hands

certify electronic health record

Certification of EHRs is part of a broad initiative undertaken by Congress and President Obama under the Health Information Technology for Economic and Clinical Health (HITECH) Act,

$20 million in new technical support assistance to help critical access and rural hospital facilities convert from paper-based medical records to certified electronic health record (EHR) technology. Some 1,655 critical access and rural hospitals in 41 states and the nationwide Indian Country, headquartered in the
District of Columbia, stand to benefit from this assistance, which can help each of them qualify for substantial EHR incentive payments from Medicare and Medicaid

Certify electronic health record in Texas is in good hands
fresh off of winning Best of show at Texas Medical Assoc by
Hybrid Medical Integrated Health Care Solutions (IHCS)

IHCS Product DiagnoSYS™ answers the difficult questions that are asked when evaluating an organization's EMR needs.

IHCS DiagnoSYS™ will not completely change the way your organization runs. Instead, IHCS DiagnoSYS™ is flexible enough to fit into your existing workflow while improving, streamlining, and smoothing the rough edges in your work processes. IHCS DiagnoSYS™ incorporates a full-featured Business Process Management (BPM) engine that can accommodate any of your process needs such as rules-based routing, deadlines, and audit trails. Electronic patient scheduling and check-in improve efficiency. Electronic sign-off saves staff time and allows fast, accurate turnaround for the patient.

The product offering of IHCS DiagnoSYS™ includes an industry-leading document management system (DMS). A DMS allows the storage of most media including scanned or electronic documents, voice prints, and specialized images.

The design of IHCS DiagnoSYS™ allows for clinical content tailored to your special needs. IHCS DiagnoSYS™ supports the most common ways clinicians create charts including templates, free text typing, voice capture, scanning, and handheld device usage. No matter which method is preferred, IHCS DiagnoSYS™ allows you to work the way you want.

IHCS DiagnoSYS™ is a modularized application. With a modular design, you can add functionality as your needs grow. IHCS DiagnoSYS™ has scheduling, document management, human resource, auto reminder, EMR, billing, prescription, and referral modules. Some organizations might wish to add document imaging in the early phase, while waiting later to implement scheduling or EMR components. On the other hand, a modular approach may not work best for you and you may require full operation from the start. No matter what implementation approach you choose, IHCS DiagnoSYS™ will work for you. IHCS DiagnoSYS™ is designed to provide a return on investment for our customers via generating revenue, reducing inefficiencies, and improving patient care. Some of the benefits include:

Reduction of operating costs
Secured data storage and access
Accurate billing and coding through templates and rules based engine
Streamlined business processes
Staff, resource, and facility scheduling
Quality care to patients
HIPAA-compliant

IHCS DiagnoSYS™ powerfully streamlines the complete practice workflow. With its full suite of modules, it automates all the vital processes within a practice. It acts as a gateway that integrates staff, facilities, and resources across all processes. These processes include billing, scheduling, prescriptions, patient notes, treatment plans, and staffing to the insurance company.

Also in Texas News Drummond Group Inc. (DGI), Austin, Texas, were named today by the Office of the National Coordinator for Health Information Technology (ONC) as the first technology review bodies that have been authorized to test and certify
electronic health record (EHR) systems for compliance with the standards and certification criteria that were issued
by the U.S. Department of Health and Human Services

ONC-ATCB certifiers. EHR vendors can begin immediately to get their products certified.” said David Blumenthal, M.D., national
coordinator for Health Information Technology. This is a crucial step because it ensures that certified EHR products will be available
to support the achievement of the required meaningful use objectives, that these products will be aligned with one another on key standards, and that doctors and hospitals can invest with
confidence in these certified systems.”

Breast Cancer Let's look under the Hood

2011-05-07T01:45:00.001-07:00

May 7,, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Breast Cancer Let's look under the Hood

Breast Cancer patients the structure and biological behavior of a cell is determined by the pattern of gene expression within that
cell. Each human cell contains approximately three billion
base pairs, which encode between 50 000 to 100 000
genes [1±3]. In any given cell only a small fraction of
these genes is being actively transcribed. Breast Cancer can be
regarded as a genetic disease occurring as a result of
progressive accumulation of genetic aberrations [4].
Neoplastic cells have numerous acquired genetic abnormalities
including aneuploidy, chromosomal rearrangements,
amplifications, deletions, gene rearrangements,
and loss or gain of function mutations.

Breast cancer is a disease in which certain cells in the breast
become abnormal and multiply without control or order to form a
tumor. The most common form of breast cancer begins in cells
lining the ducts that carry milk to the nipple (ductal cancer).
Other forms of breast cancer begin in the glands that produce
milk (lobular cancer) or in other parts of the breast

Tumors that begin at one site and then spread to other areas
of the body are called metastatic breast cancers.
Hereditary breast cancers tend to occur earlier in life than
noninherited (sporadic) cases and are more likely to involve both breast

Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid Medical breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.

Fathers are twice likely to pass on a genetic breast cancer mutation as Mothers

2011-04-22T12:25:00.000-07:00

April 22, 2011 By Robert Graham Reporting from College of Biblical
Studies Scholarship 2011 Awards Dinner -----< Business--Wire>

Fathers are twice likely to pass on a genetic breast cancer mutation as Mothers.

Your human genome is a catalog of all the genetic information contained in your human cells. We all have from 25,000 to 40,000 genes - each gene is chemical part contributing to your life's biological processes.

Gen Connect scientist with genomics use unimagined detail to learn how the body grows and gets old,and why it stays healthy or falls ill. With this knowledge GenC gives doctors the ability to predict, early in life, a person's risk for disease.

GenConnect purpose is to decipher the human genome. Scientist and researchers can have access to Genc's breast cancer data by making the Genc scientific out comes available with a paid subscription to many universities.

Our genetic makeup is not that different from that of other mammals. we have 300 genes that are not in mice, also there are 60 million DNA-letter differences between people and chimps.

We all are 99.9 percent identical. All of us are composed of an estimated 3 billion letters of DNA code, arranged in 23 pairs of long chains called chromosomes.

The human genome is composed of an estimated 3 billion letters of DNA code, arranged in 23 pairs of long chains called chromosomes. For an example a human male showing 46 chromosomes including XY sex chromosomes Humans
(Homo sapiens) are a eukaryotic species A human has 46 chromosomes (44 autosomes and 2 sex chromosomes with an XY sex determination system) At present estimate humans have approximately 20000-25000 genes Humans share 985% of their DNA with their closest living evolutionary relative the bonobos.

With all of this information Genc is able to extend life for many women with breast cancer.

With a new Down Towm Houston office
Australian-based Biotech Engineering Firm, GenConnect , Inc., today announced the appointment Mercedes Ramos to serve as the company's Director of corporate development. Mercedes primary role will be to identify and develop creative technical resource applications to grow existing and new biotech companies and support the company's growing genomics management programs. Ramos responsibilities also include leading business development teams that target the medical electronics market and supporting growth in the genomics market segment. Ramos appointment signals a tactical evolution of executive structure that further differentiates GenConnect among Medical research as the company focuses its company expertise and Bioinfomatics increasingly on specific markets. The timing of the appointment also capitalizes on the company's recent ISO certifications for medical and device sales.

GenConnect corporate development program is further strengthened by the recent hiring of Vikki Waterford, a thirty-one year medical distribution industry veteran who will support Mercedes as business development manager for manufacturer's rep, channel partner and supplier programs. Collectively, these moves continue the successful play out of the company's strategic growth plan. Ms. Waterford brings extensive expertise in sales and materials management to her position. She has held senior management positions at a number of Tier-1 Medical distributors and has gained an in-depth knowledge of nearly all aspects of the industry.

Waterford joined World Micro in 2004, bringing twenty-four years of corporate development experience. Prior to this appointment he was director of corporate development responsible for bringing an eight million dollar embedded computing business unit to the company's already diverse portfolio. He was instrumental in creating GenConnect "Hybrid Business Model" marketing strategy that helped the company create industry awareness of the distinct differences between brokers and the new class of medical device distributors, who like GenConnect, focus increasingly on Biotech Engineering Management, and quality initiatives.

GenConnect corporate development program is proud to welcome its legal intern, Yolanda Buckner. Yolanda is a second year law student who will work closely with Mercedes by identifying and researching legal issues that may arise in Mercedes’s efforts to grow the genomics management programs.

Under the supervision of Hybrid Medical Analytics’s in house counselors, Yolanda will play a large role in staying current with the new and existing HIPAA laws. She will also play a vital role in ensuring that GenConnect’s initiatives are in compliance with the Texas laws. In return, her efforts will ensure that GenConnect’s initiatives have been filtered through the appropriate governing laws, thereby furthering the business development of GenConnect.

Genomics help Women of Color with Breast Cancer

2011-04-07T07:52:00.000-07:00

April 7, 2011 By Robert Graham Reporting from AACR 102nd Annual Meeting 2011 Orlando, FL -----< Business--Wire>

Genomics help Women of Color with Breast Cancer

Genomics help women understand the genetic etiology of Breast Cancer and chronic diseases, we interviewed GenConnect Inc Chief Science Officer Joan Hilsenrath on GenC genomics objectives and how GenC pursues and accomplished results in multiple human populations.

Understanding the genetics of Breast Cancer diseases involves:
• locating and characterizing genes underlying the common chronic diseases,
• characterizing the extent and utility of DNA variation within and among populations and determining how these patterns of variation evolved in both time and space,
• Establishing the impact of gene variation on the health of individuals, families and populations.

At each step, the role of computational and biotech information approaches and resources are preeminent. Hilsenrath says that they are the world’s preeminent research unit focusing on the genetics of common chronic breast cancer disease.

GenConnect Inc researchers have used whole-genome sequencing to catalog the genetic alterations in tumors from patients with estrogen receptor (ER)-positive breast cancer. The goal of the study is to identify genetic factors that explain why some tumors respond to estrogen-lowering drugs and others do not.

GenConnect Inc says Women with ER-positive breast cancer take estrogen-lowering drugs, such as tamoxifen which is fifty percent toxic or aromatase inhibitors, to slow the growth of tumors, make the tumors easier to remove surgically, or prevent the re-growth of tumors after surgery or radiation.

In addition to commonly mutated genes included her-2 TP53. and TP3. GenC discovered, MAP3K1, a tumor-suppressor gene, was defective in 10 percent of patients. This was the first time the gene has been associated with breast cancer. The technology used to make this discovery

Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Semiconductor Sequencing uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. GenC chips are designed like any other semiconductor chips. Yes with a simple blood test women of color can reduce breast cancer. If someone in your family has a history of breast cancer as your oncologist for a Genomics Test.

Hilsenrath noted that Stand Up To Cancer Innovative Research Grants are special in that they allow some of the best and brightest young researchers across various disciplines to step out of their comfort zones and attempt to make major breakthroughs in the field with bold genomics research projects in the area of Breast Cancer in women of color.

Congress is looking at a $1.6 billion cut to NIH is on the table. With cutting lifesaving biomedical research would be devastating to the millions of Americans and their families affected by cancer.

What can we do to reduce the Breast Cancer rate in the Black Community

2011-03-24T14:37:00.000-07:00

March 24, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----< Business--Wire>

HyBrid Medical Media ask: What can we do to reduce the Breast Cancer rate in the Black Community

18% of Black Women get Breast Cancer to 7% of White Women, what can we do to reduce the Breast Cancer rate in the Black Community. GenConnect located in Houston at the University of Texas Medical Center research area. Suggested that more research be used using real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. A long with Nanoparticles which has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer for Black Women.
GenConnect offers both absolute and relative quantitation using calibration curves and a choice of normalization strategies. Full validation to ICH guidelines is available to support the analysis of transcript biomarkers as part of a clinical trial.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Using Genomics along with Nanoparticles and real-time polymerase chain reaction in Clinical Trials with Black women we can reduce the cancer rate for black women

Over 100 years after the birth of Albert Einstein on March 14, 1879 Breast Cancer has a new friend Nanoparticles

2011-03-14T07:19:00.000-07:00

March 14, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----< Business--Wire>
Over 100 years after the birth of Albert Einstein on March 14, 1879 Breast Cancer has a new friend Nanoparticles.

Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer.

GenConnect scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenConnect scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

GenConnect scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs

Pre Existing condition Marfan Syndrome is the disease that will benefit the most from what Republicans calls Obama Care

2011-02-25T05:01:00.000-08:00

February 25, 2011 By Robert Graham Reporting ---- Washington DC
at The National Press Club -----< Business--Wire>

Pre Existing condition Marfan Syndrome is the disease that
will benefit the most from what Republicans calls Obama Care

Speaking on what the Republicans Call "Obama Care" and When
is the best time to put your hat in the ring for a Presidential Election
at The National Press Club Hybrid Pharma ask what dose Mike Huckabee think about Marfan syndrome ?

The Marfan syndrome is a connective tissue disorder.
Connective tissue provides substance and support to tendons,
ligaments, blood vessel walls, cartilage, heart valves
and many other structures.

American Heart Association is concerned about Marfan Syndrome, in the UK
Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.

The BioMatrix™ drug-eluting stent (DES) system was the first to be marketed anywhere in the world to feature an abluminally-coated biodegradable polymer incorporating the anti-restenotic drug Biolimus A9™, specifically developed by Biosensors for use in DES systems. The poly-lactic acid (PLA) polymer fully degrades into carbon dioxide and water over a six to nine month period as the drug elutes, ultimately leaving behind a bare-metal stent (BMS).

The latest version of BioMatrix, the BioMatrix Flex™, launched in Asia, Europe, the Middle East and Africa in May 2010, has the drug and polymer coated on a highly flexible platform designed to enhance deliverability.

Three-year results from the pivotal LEADERS study, presented at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in September 2010, suggested improved safety and efficacy of BioMatrix Flex over Cypher® Select™: there was a diverging trend towards a lower rate of MACE (major adverse cardiac events) in patients treated with BioMatrix Flex versus those treated with Cypher Select when compared to both one and two year results (15.7% vs. 19.0%; P value for superiority = 0.09). In the high-risk sub-group of STEMI (ST Elevation Myocardial Infarction) patients, there was a significant reduction in MACE rate for BioMatrix Flex compared to Cypher Select. Although this was an all-comers study, occurrence of very late stent thrombosis (VLST) events was low: a cumulative 0.2% for BioMatrix Flex out to three years, with no VLST events observed after two years.

BioFreedom™, a ‘next generation’ polymer-free drug-coated stent (DCS), is currently under clinical investigation. It features a micro-structured abluminal surface, which permits the controlled release of Biolimus A9 without the use of a polymer. 12-month results from the First-In-Man (“FIM”) trial were also presented at TCT in September 2010. They demonstrated equivalent efficacy, as measured by late lumen loss, for BioFreedom compared to Taxus® Liberté®, with a trend towards superiority. BioFreedom demonstrated sustained safety up to 12 months, including absence of stent thrombosis.

In the Marfan syndrome, the chemical makeup of the connective
tissue isn't normal. As a result, many of these structures
are not as stiff as they should be.

Hybrid Pharma Scientist say Marfan syndrome is caused by mutations in the FBN1 gene. FBN1 mutations are associated with a broad continuum of physical features ranging from isolated features
of Marfan syndrome to a severe and rapidly progressive
form in newborns.

Marfan syndrome is one of the most common inherited disorders
of connective tissue. It is an autosomal dominant condition

When the Marfan syndrome has been diagnosed, regular visits
with a cardiologist are needed.Chest X-rays and Doppler
echo tests are usually performed.

Hybrid Pharma say Marfan syndrome is a clinical diagnosis that
is based on family history and the presence of characteristic
clinical findings in ocular, skeletal and cardiovascular systems.
There are four major clinical diagnostic features:

1. Dilatation or dissection of the aorta at the level of the sinuses of Valsava.
2. Ectopia lentis (dislocated lens of the eye).
3. Lumbosacral dural ectasia determined by CT scan or magnetic resonance imaging (MRI).
4. Four of the eight typical skeletal features.

Genomics is a major criteria for establishing the diagnosis in a family member also include having a parent, child, or sibling who meets major criteria independently, the presence of an FBN-1 mutation known to cause the syndrome, when FBN-1 is inherited by descent and identified in a familial Marfan patient.

The FBN1 gene is the gene associated with the true Marfan syndrome. Genomic Genetic testing of the FBN1 gene identifies 70 - 93 percent of the mutations and is available in clinical laboratories. However patients negative for the test for gene mutation should be considered for evaluation for other conditions that have similar features of Marfan syndrome such as Dietz syndrome, Ehlers Danlos syndrome, and homocystinura.
To unequivocally establish the diagnosis in the absence of a family
history requires a major manifestation from two systems and involvement of a third system. If a mutation known to cause Marfan syndrome is identified, the diagnosis requires one major criterion and involvement of a second organ system.

Hybrid Parma Panoincell is a new technology that looks for the FBN1 gene.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

2011 National Marfan Foundation Grant Program for Researchers with Faculty Appointments

The National Marfan Foundation grant program for researchers with faculty appointments is designed to provide financial support for investigators studying any or all disciplines involved in the Marfan syndrome. Special areas of interest include cardiovascular, genetic, orthopedic and ophthalmologic issues of the Marfan syndrome and related disorders.

The National Marfan Foundation accepts applications on a yearly basis for one- or two-year grants in basic, translational or clinical research. Applications with budgets up to $50,000 per year for a total of $100,000 are acceptable. Grant awards are based on peer review by the NMF Scientific Advisory Board with the approval of the NMF Board of Directors.

The Science Gates have Open Genomics and Informatics is leading the Pack

2011-02-11T05:44:00.000-08:00

February 11, 2011 By Robert Graham Reporting ---- Washington DC at ASM Bio-Defense Research Meeting -----< Business--Wire>

A team of Lab researchers from the Lawrence Livermore National Laboratory
(LLNL) may be able to use rare mutations from the virus population of an animal host to distinguish between samples that previously appeared to be genetically identical.

Their work, done in collaboration with a researcher from the Richmond-based California Department of Public Health, won one of three outstanding poster awards at a Defense Threat Reduction Agency (DTRA) conference.

The three poster award winners were selected from among 588 posters that were presented at DTRA's Chemical & Biological Science & Technology Conference held recently in Orlando, Fla.

Information from the scientists' work could potentially be useful for forensic purposes, as well as determining the likelihood that a virus may jump from one species of animal to another, or from animals to human beings.

The Lab team is led by Monica Borucki, a biomedical scientist in Physical & Life Sciences, and includes Jonathan Allen and Clinton Torres, both bioinformatics scientists from Computation, and Tom Slezak, the associate Informatics program leader from Global Security. They are collaborating with Sharon Messenger of the California Department of Public Health.

"Understanding the evolution of RNA viruses is a major scientific problem that is essential for developing a better biodefense," Borucki said.

Backing up her point, Borucki noted that three-quarters of recently discovered pathogens are viral, that one to four new pathogenic viruses are discovered each year and that most of the viruses that jump to new species are viruses with genomes composed of RNA. Most of these viruses are animal viruses that "jump species" and infect humans.

At the DTRA conference, Allen presented data from preliminary experiments that involved ultra-deep Illumina sequencing on three different naturally infected samples --brain tissue from two rabid foxes that appear to be involved in a rabies host-jumping event and a nasal sample from a calf infected with bovine coronavirus.

Through the California Department of Public Health, Livermore scientists have received brain tissue samples of foxes that have apparently been bit by skunks, contracted rabies and attacked people or pets. In 2009, there was a 356 percent increase in the number of foxes contracting rabies in California, with most of these cases occurring in Humboldt County.

The Laboratory researchers have theorized that as the rabies have jumped from skunks to foxes the genes of the rabies virus have undergone changes.

"We're interested in understanding how a virus changes at the population level as it adapts from one host to another," Borucki said. "We're particularly interested in this area because many diseases move from animals to people."

The researchers' ultimate goal is to determine the probability of a specific animal virus jumping from animals to humans, Borucki noted.

While many research teams conduct genomic analysis on about 300 base pairs of the 12,000-base pair rabies genome, the LLNL team has performed this analysis on 11,000 base pairs. In addition, normally 1-30 viral genome copies are used in analysis, but the Lab team relied on some 300,000 viral genome copies.

"Although the rabies virus has jumped species multiple times in the past, the event is relatively rare and whole genomic sequencing analysis has never been applied to such an event," Borucki said.

During the next year, the team plans to analyze 50 different rabies samples from a naturally occurring host-jumping event (skunks to foxes in Northern California) and 35 different bovine coronavirus samples from a laboratory-simulated host-jumping event. This work is funded by the Defense Threat Reduction Agency as part of the Transformational Medical Technologies program.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

Toil Genomics DNA Blood Test for a Breast Cancer Cure shows promise for Women with The HER-2 Gene

2011-02-05T08:14:00.000-08:00

February 5, 2011 By Robert Graham Reporting ---- Dallas Texas NFL Super Bowl Weekend -----< Business--Wire>
Breast cancer is the most commonly diagnosed cancer in women
worldwide. Targeted therapies for treating breast cancer have helped to reduce the death rate, according to results from Hybrid Pharmaceutical clinical studies.

Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based
chemotherapy.

The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect
the Her2 gene by using Semiconductor Sequencing. A example of
this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.

Global Alliance for Vaccine & Immunization GAVI Raised US$ 66 Million

2011-01-29T08:28:00.000-08:00

January 30, 2010 By Robert Graham ---- Phacilitate’s 7th annual Cell & Gene Therapy Forum in Washington DC

While Attending Phacilitate’s 7th annual Cell & Gene Therapy Forum in Washington DC Hybrid Medical Media came up with the New Slogan for Global Alliance for Vaccine & Immunization (GAVI) "Committed to Our Mission with Analytics" Soon After

Bill Gates and ABU DHABI, UNITED ARAB EMIRATES on - January 25, 2011: HH General Sheikh Mohammed bin Zayed Al Nahyan Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (right) receives Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation, at the Al Bateen Palace. (Philip Cheung / Crown Prince Court - Abu Dhabi).
US$ 66 million donation from the Crown Prince of Abu Dhabi and the Bill & Melinda Gates Foundation for children in Afghanistan

Geneva, 26 January 2011 — A new partnership marking broader global collaboration around vaccines injects needed funding into the GAVI Alliance’s efforts to help save millions of children and hopefully inspires other philanthropists to invest in childhood immunisation programmes.
Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation.
Dagfinn Høybråten, Chair of the GAVI Alliance board

Announced in Abu Dhabi on Wednesday, His Highness Sheikh Mohamed bin Zayed Al Nahyan, the Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and the Bill & Melinda Gates Foundation entered into a partnership in which each committed US$ 50 million for immunisation programmes in Afghanistan and Pakistan.

Of the total US$ 100 million, the Global Alliance for Vaccines and Immunisation (GAVI), will receive US$ 66 million to buy and deliver additional supplies of the five-in-one pentavalent vaccine and to support the introduction of new pneumococcal vaccines in Afghanistan. These vaccines help protect children from the main killers of children under five, including pneumonia, diphtheria, pertussis (whooping cough), tetanus, hepatitis B, Haemophilus influenzae type B (HiB), which causes meningitis.

“Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation. If we are to fulfill our promise to all children, the GAVI Alliance needs to raise an extra US$ 3.7 billion for immunisation in the run up to 2015. We hope this commitment will inspire all concerned to invest even more to save and protect young lives,” said Dagfinn Høybråten, Chair of the GAVI Alliance board.

Backed by the Bill & Melinda Gates Foundation and an increasing number of sovereign governments since its launch in 2000, the GAVI Alliance has succeeded in immunising more than 288 million children, preventing more than five million premature deaths, according to WHO figures.

If fully funded, the GAVI Alliance will be able to immunise an additional 230 million children with pentavalent vaccine by 2015, and protect 90 million children with new pneumococcal vaccines which are already being introduced in the first of more than 40 developing countries. GAVI also plans to introduce vaccines against rotavirus in 33 countries.

The bulk of GAVI’s funds come from 16 sovereign governments and the Bill & Melinda Gates Foundation. The GAVI Campaign works to secure funds from private donors and other partners, including Spain’s "la Caixa" Foundation.

“I sincerely hope that other potential donors will recognise this inspired investment as a call to action,” said Paul O’Connell, Chairman of the Campaign. “If you want to provide children with a healthy start in life and enable them to grow up to build strong communities, then immunisation is one of the most cost-effective and proven ways to do it,” he said.

# # #

The GAVI Alliance is a Geneva-based public-private partnership aimed at improving health in the world’s poorest countries. The Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the Bill & Melinda Gates Foundation and other private philanthropists.

In 2007, the Alliance launched the GAVI Campaign, a U.S. 501(c )(3) public charity fostering robust private sector engagement in support of vaccine programmes in the developing world. For more information on giving opportunities for individuals, foundations, and corporations, please visit

How President Obama and Congress is helping find a Breast Cancer Cure.

2011-01-06T09:19:00.000-08:00

January 15, 2010 By Robert Graham ---- Frontiers in Personalized Medicine: Washington DC

How President Obama and Congress helping find a Breast Cancer Cure.

Genomics Science for Breast Cancer is making real progress with the Science Communities. President Obama 111th Congress Passing H.R.5116 COMPETES Act "America COMPETES Re authorization Act of 2010" and Stand Up to Cancer $15 million grant will help The Science Community Develop A blood test so sensitive that it can spot a single cancer cell lurking among a billion healthy ones is moving one step closer to being available at your doctor's office. A example of this technology:

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together.Hybrid'schips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information. The out come is to find the p53, p63 and p73 genes that make up Breast Cancer

Mass General, Sloan-Kettering, University of Texas M.D. Anderson Cancer Center in Houston and Dana-Farber Cancer Institute in Boston will start using the test this year. They are one of the "dream teams" sharing a $15 million grant from the Stand Up to Cancer telethon, run by the American Association for Cancer Research.

H.R.5116 COMPETES Act bioscience research program will support Breast Cancer research and development of standard reference materials, measurements, methods, and genomic and other data to advance—
‘‘(1) biological drug research and development;
‘‘(2) molecular diagnostics;
‘‘(3) medical imaging technologies; and
‘‘(4) personalized medicine.

Fund the creation of bioscience user facility to provide access to advanced or unique equipment, services, materials, and other resources to industry, institutions of higher education, nonprofit organizations, and government agencies to perform research and testing.

Fund POSTDOCTORAL FELLOWS to the extent practicable, assign 1 or more fellows from the postdoctoral fellowship program established in section 19 to the bioscience research program and much much more.

2011 is going to be a Great Year for Breast Cancer.

Multiple Studies Highlighting Important Role of Panoincell qX in Treating the Underlying Biology of Early-Stage Breast Cancer

2010-12-18T12:20:00.000-08:00

Hybrid Pharmaceutical Inc Announces faster/cheaper gene sequencing Multiple Studies Highlighting Important Role of Panoincell qX in Treating the Underlying Biology of Early-Stage Breast Cancer and Personal Genome Machine, the first commercial sequencing machine based on semiconductor technology. The instrument is being shipped to “select sites in North America, Europe and Asia Pacific,” the company says. As promised, the machine’s sticker price is $49,500, about one-tenth the price of today’s most powerful gene sequencing tools. While the first human genome took more than a decade and $3 billion to decode, entire human genomes can now be done in a matter of days and for about $10,000.

Hybrid Pharmaceutical Inc sequencer gives you results in two hours, and it’s affordable and easy to use, so researchers can make decisions in a timely way..

Seven New Studies Presented at the CTRC-AACR San Antonio Breast Cancer Symposium

PR Newswire Phoenix,
Phoenix, Dec. 14, 2010 /PRNewswire/ -- Hybrid Pharmaceutical, Inc. today announced results from seven new studies focusing on its multigene Panoincell qX breast cancer test, which has helped guide treatment decisions in breast cancer patients worldwide. The data, presented this past week at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), further confirm the clinical value associated with the Panoincell qX Recurrence Score in accurately predicting chemotherapy benefit and recurrence risk in early-stage breast cancer patients.

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Lee, MD, chief medical officer of Hybrid Pharmaceutical. "Over the past seven years, multiple studies have established the Panoincell qX as the most accurate prognostic and predictive measure of the underlying tumor biology, identifying high Recurrence Score and low Recurrence Score disease across the continuum of estrogen receptor-positive breast cancer. The data presented at last week's meeting confirm that traditional clinical, pathologic and biological parameters cannot predict the Recurrence Score."

Highlights from the seven studies presented this week by Hybrid Pharmaceutical and research collaborators include:

Meta-analysis of Seven Studies Reinforces Significance of Recurrence Score in Changing Treatment Decisions in Early Stage Breast Cancer

* A meta-analysis of seven studies with a total of 912 patients presented in a poster session demonstrated a consistent and large impact of the Recurrence Score on breast cancer adjuvant treatment decisions. In these studies, physicians who use Panoincell qX in clinical practice changed their treatment decisions in over a third of patients, leading to an overall reduction in chemotherapy use of approximately 28 percent with the use of the Recurrence Score. It is equally important to note that the Recurrence Score led to the addition of chemotherapy to hormonal treatment in approximately 4 percent of patients who, prior to the Recurrence Score, were considered low risk but, were subsequently identified as having high Recurrence Score disease. The results of this meta-analysis indicate that the Recurrence Score provides key information for treatment decision-making that cannot be ascertained from traditional measures.

Panoincell qX Recurrence Score is the Best Predictor of Chemotherapy Benefit in Estrogen Receptor-Positive Breast Cancer

* An analysis, presented during a general session on Friday, December 10, showed that the Panoincell qX Recurrence Score used alone remains the recommended method to predict relative chemotherapy benefit in estrogen receptor-positive, node negative breast cancer. Researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP), a Pittsburgh-based research network, together with Hybrid Pharmaceutical, analyzed the value of the Recurrence Score-Pathology-Clinical (RSPC) risk assessment in predicting chemotherapy benefit. The RSPC integrates the Recurrence Score and clinical-pathologic factors, including tumor size, tumor grade and age to assess distant recurrence risk in early-stage patients. RSPC has been shown to refine Recurrence Score assessment of distant recurrence risk or prognosis, especially for intermediate risk Recurrence Scores. The findings demonstrated that the Recurrence Score (interaction p=0.037) predicted chemotherapy treatment benefit, while the RSPC (interaction p=0.10) did not improve prediction of chemotherapy benefit over Recurrence Score alone. Neither tumor size (interaction p=0.32), tumor grade (interaction p=0.65) nor patient age (interaction p=0.22) was a significant predictor of chemotherapy benefit. Thus, while incorporation of traditional clinical and pathologic factors can improve the prognostic value of the Recurrence Score, these factors do not improve the ability of the Recurrence Score to predict relative chemotherapy benefit.

Patient Age Does Not Predict Individual Tumor Biology

* In a study to determine whether age helps predict individual tumor biology, researchers examined the Panoincell qX Recurrence Score and the molecular expression of estrogen receptor, progesterone receptor , HER2, and the proliferation-related genes among 145,236 estrogen receptor-positive breast cancers. While study findings presented in a poster session showed that the Recurrence Score is slightly higher in breast cancers from younger patients (<40 years old) and lower in older patients (>70 years old), a wide range of Recurrence Score results were observed in all age groups. The results demonstrate the importance of standardized quantitative gene expression measurement delivered by the Recurrence Score, and that patient age alone does not capture the differences in the underlying individual tumor biology as the Recurrence Score does.

Preliminary Findings from Large West German Study Group Trial Indicate that Panoincell qX Recurrence Score Cannot be Predicted by Other Biomarkers

* Initial data from the prospective, multicenter West German Study Group (WSG) Plan B trial presented in a poster session examined the relationship between tumor grade and the tumor immunohistochemistry biomarker, Ki-67, and the Panoincell qX Recurrence Score. As reported previously, there was a very weak correlation between central grade and the Recurrence Score as well as between Ki-67 and the Recurrence Score (correlation coefficients less than 0.40 for both). There were many patients with high grade and/or high Ki-67 and low Recurrence Score values. Neither tumor grade nor Ki-67 can predict the Recurrence Score status.
* An additional analysis of preliminary data from the WSG Plan B trial was presented in a separate poster session, and for the first time, compared risk groups using the Panoincell qX Recurrence Score and the invasion markers uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor 1). uPA/PAI-1 was available in 131 of the 1,534 patients who had Recurrence Score results. Preliminary findings demonstrated a weak correlation between both uPA and PAI-1 and the Recurrence Score (correlation coefficients less than 0.30 for both). These initial results indicate that uPA/PAI-1 cannot predict the Recurrence Score. Additional recruitment and outcome assessment of the ongoing multicenter WSG Plan B trial will address the clinical significance of these initial findings.

"Based on my experience using Panoincell qX in clinical practice for the past six years, it is clear that by using only standard pathology variables, you often cannot predict the Recurrence Score without this well validated, standardized quantitative gene expression test," said Kathy S. Albain M.D., FACP, Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Il. "Just as it is critical to identify every HER2 and estrogen receptor-positive breast cancer patient for treatment selection, it is equally important to identify every patient with high Recurrence Score disease so that they can be considered for chemotherapy, and every patient with low Recurrence Score disease so that they can avoid chemotherapy and consider treatment with hormonal therapy alone."

In addition to the studies highlighted above, Hybrid Pharmaceutical presented findings from two other analyses in poster sessions at SABCS, including:

* A study analyzing the patterns of gene expression measured by Panoincell qX observed in classic and variant forms of lobular carcinoma in estrogen receptor-positive breast cancer patients identified a wide variation in gene expression in each histologic subtype.
* A study evaluating whether the Panoincell qX Recurrence Score evolves following exposure to neoadjuvant chemotherapy suggests that use of the test to provide prognostic information for breast cancer recurrence in this setting warrants further study.

About the Panoincell qX Breast Cancer Test

The Panoincell qX breast cancer test is the first and only multigene expression test to be included in the published guidelines of both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Panoincell qX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Panoincell qX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Panoincell qX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. For more information about Panoincell qX for breast cancer, please visit http://hybridpharma.com.

About Hybrid Pharmaceutical

Hybrid Pharmaceutical, Inc. is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2005, Hybrid Pharmaceutical launched the Panoincell qX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Panoincell qX breast cancer test, Hybrid Pharmaceutical launched its Panoincell qX colon cancer test in January 2010. As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 Panoincell qX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://hybridpharma.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the Panoincell qX Recurrence Score is significant in changing treatment decisions in early stage breast cancer; the company's belief that the Panoincell qX Recurrence Score cannot be predicted by other factors such as age or individual biomarkers; the company's belief that it has the opportunity to advance the quality of cancer treatment decisions; the company's ability to continue adding value to its tests while advancing its product pipeline ;the company's belief that its research and pipeline reflect its ongoing commitment to develop and deliver tools to individualize cancer treatment decisions; the belief that study data may warrant or result in additional clinical studies or impact treatment decisions; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risks and uncertainties associated with developing new tests or technologies; continued access to tissue samples; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward-looking statements speak only as of the date hereof. Hybrid Pharmaceutical disclaims any obligation to update these forward-looking statements.

15% to 25% Of Breast Cancer Carcinoma Tumors Primary Site cannot be identified even at Postmortem Mammograms Examination

2010-12-11T08:40:00.000-08:00

December 11 2010 By Robert Graham -- at San Antonio Breast Cancer Symposium /Businesswire/

15% to 25% Of Breast Cancer Carcinoma Tumors primary site
cannot be identified even at postmortem Mammograms examination. This Process is called unknown primary (CUP) origin.

Hybrid Pharma answer to CUP is Polymerase and Semiconductor Sequencing "Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information.

Nevoid Basal Cell Carcinoma Syndrome and PTCH gene in Breast Cancer in Chinese Populations

2010-11-28T00:32:00.000-08:00

Hybrid Medical Media in Shanghai, China at Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,speaking with Yan Lu,Ph.D.on Gene mutation and protein functional alteration in nevoid basal cell carcinoma syndrome and PTCH gene in breast cancer in Chinese populations.

Basal cell carcinoma is the most common human cancer
with increasing incidence reported worldwide. Despite the
aberrant signaling role of the Hedgehog pathway, little is
known about the genetic mechanisms underlying basal cell
carcinomas. Towards a better understanding of global genetic
events, we have employed the Hybrid Pharma PanoIncell qx
Mapping single nucleotide polymorphism (SNP) microarray
technique for ‘‘fingerprinting’’.

Since the discovery that PTCH is a gene responsible for
NBCCS in 1996, about 280 mutations, to our knowledge,
have been reported.

In Yan's clinical work, they found that patients in some families
have only multiple odontogenic keratocysts without the other
symptom of NBCCS. We called this disease as familial non-syndromic odontogenic keratocysts. Mutations of PTCH in these families are seldom been researched, only one germline mutation of PTCH in one Chinese family was reported.

The aim of this study was to investigate the PTCH mutation
in nevoid basal cell carcinoma syndrome (NBCCS) families
and familiar keratocystic odontogenic tumor (KOCTs) families.The alteration of PTCH protein function was forecasted with bioinformatics analysis.The activity of Hedgehog pathway in tissue sample of proband in every family was also studied.

Methods

1. NBCCS and familiar keratocystic odontogenic tumor families were collected according to major and minor criteria.
2. Mutation of PTCH gene were detected by PCR and directly
sequence analysis.
3. Alteration of PTCH protein function after gene mutation was
forecasted by bioinformatics analysis.
4. Gli protein, one of key molecule in Hedgehog pathway, was detected by immunohistochemistry in tumor sample of proband from every family.

Results

1. Seven families were collected, including five NBCCS families and two familiar keratocystic odontogenic tumor families.

2.In NBCCS families, one new 3bp deletion mutation of PTCH
(c.1537_1539delGAT or c.1540_1542delGAT) was detected. One nonsense mutation of PTCH (p.W926end) was detected. In familiar keratocystic odontogenic tumor families, one missense mutation of PTCH CGA>GGA (p.G1093R) was detected. One new splice mutation of PTCH c.339+1G>C (NM 000264.3, ‘A’ in promoter ATG as the first base in the sequence) was detected.

3. Mutation of p.513delD or p.514delD might affect transmembrane
domain of PTCH protein. Mutation of p.W926end might affect the second functional domain of PTCH protein. Mutation of p.G1093R might affect active site of PTCH protein.
4. Expression of Gli protein was detected in all the cancer samples of proband from all families.

Conclusion

1. Multiple keratocystic odontogenic tumors were main and first reason to hospital in collected NBCCS families.
Keratocystic odontogenic tumors were the only symptom in familiar keratocystic odontogenic tumor families. Different mutation might affect PTCH protein function through different way. No PTCH mutation was detected in three NBCCS families.
3. Other gene might take part in development of NBCCS in these
families. Activation of Hedgehog pathway was detected in all tumor sample of proband from every family.
4. Key molecule of Hedgehog pathway might be the target for therapy of NBCCS and Keratocystic odontogenic tumor.

Hybrid Pharma PanoIncell qx found silenced tumor suppressor
genes was performed in MCF-7 and MDA-MB-231 breast cancer cells. Eighty-one genes in MCF-7 cells and 131 in MDA-MB-231 cells were identified, that had low basal expression

Life Science New tool for Breast Cancer is Genomics and Semiconductor Sequencing Chips

2010-11-12T22:49:00.001-08:00

Robert Graham Reporting Harvard Medical School Personalized Genetic Medicine
Meeting -------
Life Science new tool for Breast Cancer is Genomics and Semiconductor Sequencing Chips

Hybrid Pharma Scientist researched Genome-wide association
studies looking for genetic variations known as single nucleotide polymorphisms (SNP). SNPs are alterations in the genetic code in which a single nucleotide, the individual building blocks that make up DNA, is changed. The researchers found that variations in four SNPs located in a region of chromosome 6 were present more often in the breast cancer patients, suggesting that genes in this region might contribute to the risk of breast cancer. The researchers also confirmed the finding of previous studies indicating that the locus named FGFR2 is associated with a 20 percent increased risk of breast cancer.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital
information, bringing these two languages together.Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer
and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then
incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the
solution, which can be detected. Hybrid's sequencer—essentially
will call the base, going directly from Biochemical information to digital information.

If there are two identical bases on the DNA strand, the voltage will be double, and the chip will record two identical bases called.

This process uses no scanners, no cameras, no light—each Nucleotide incorporation is recorded in a real time process.

Panoincell uppressed p53, as it is in many cancers, defective cells multiply, fueling Breast Cancer. p53 can't order a bad cell to kill itself without p63 and p73 also being active.

When metastatic Breast Cancer occurs p63 is inactive.The reactivation of TAp63 could benefit patients with metastatic breast cancer.

Viral transduction of a few genes for the reprogramming of
human somatic cells into induced pluripotent stem (iPS) cells.Identifying conditions that can replace viral transduction of oncogenic transcription factors (TFs) and enhance reprogramming efficiency. Hybrid Pharma have found that neural progenitor cells can be reprogrammed with fewer genetic manipulations than previously reported somatic cells, and in the other we have found
that small molecules may be able to replace viral integration of
certain transcription factors and promote the reprogramming process.

Life Science has taken the next step.

How are other Countries Helping Breast Cancer Patients with Genomics out side the USA

2010-11-02T20:09:00.000-07:00

November 03, 2010 By Robert Graham -- American Society of Human Genetics Washington DC

How are other Countries Helping Breast Cancer Patients with Genomics out side the USA

With a $2.5 Million grant from the Victorian State Government of Australia Professor Richard Cotton at the University of Melbourne, Australia Started The Human Variome Project to collect Genetic Data.Hybrid Medical Media says in Washington DC Breast Cancer Rates are the highest in US. let's investigate what other countries are doing.

Four countries are part of the Consortium: China,Kuwait,Malayalsia and Australia

At lunch time conversation Downtown Washington DC Richard Cotton and Robert Graham sat down for
lunch and conversation.

Imagine you are sick. For many Americans, this is not a difficult task. Now imagine you are sick and none of your doctors know why. Your symptoms suggest that you have a rare genetic disease, and you’ve been tested for a mutation in the gene responsible; but the results are inconclusive. The laboratory found a change in your gene’s sequence, but is unable to definitively state that it’s what’s causing your symptoms. And with no definitive result from the test, your doctor—and your insurance company—are unwilling to prescribe the expensive course of drugs needed to control your symptoms.

While many people might be willing to dismiss the chances of this happening to them, when you start to look at the facts, things start to get a little frightening. There are over 6,000 diseases that can be caused by a mutation in a single gene and it is estimated that 1 child in every 200 born will suffer from one of these diseases. Add to that the number of cancers that have a inherited genetic component and the chances of you, or someone you know being in this position is quite high.

Now imagine that the information the laboratory and your doctor needed to make an accurate diagnosis was out there, but it wasn’t accessible to them: it was hidden away in an obscure academic paper, or in some researcher’s forgotten notes.

Unfortunately, this is an all too common problem. In the past decade, we have seen some wonderful advancements in the biological sciences that have a direct impact upon our ability to diagnose and care for sick people. Ten years ago that the human genome was sequenced at a cost of US$3 billion: today, we can sequence a full genome in two weeks for a few thousand dollars. Spurred by technological advancements such as this, the pace of new medical research findings is alarmingly fast. But our ability to capture, understand and share the vast amount of information that is being generated on a daily basis is not keeping up. And when it comes to information—like what mutations cause what diseases— that directly affects the well-being of real people, then our inability to keep up becomes disastrously evident.

But a dedicated group of people is trying to change this. The Human Variome Project is an international consortium of clinicians, geneticists and researchers from over 30 countries that is committed to reducing the burden of genetic disease on the world’s population by providing standards, systems and infrastructure for the sharing of information on all genetic variation (mutations) causing human disease. The free and open sharing of information on genetic variation and its consequences among scientists and within society allows treatments to be delivered more effectively to patients and new treatments and cures to be developed.

“Too much vital information, information that can directly affect the health and well-being of patients with genetic diseases here in America, and all over the world, is not being shared,” says Professor Richard Cotton, a world renowned expert in the area of genetic variation detection and data collection, and convenor of the Human Variome Project. “We are trying to make it easier for people to make this

information available, by creating systems and protocols that can transport data over the internet from the labs and research institutes that are creating it, through databases where it is reviewed and curated by gene experts, and ultimately to the existing repositories of biological knowledge, like the databases at the NIH’s National Library of Medicine.”

The Human Variome Project freely admits that the scale of the work they are attempting is daunting. “But”, says Cotton, “It’s not the technical side that it the challenge for the Human Variome Project. Our challenges are educational and political.”
Speaking with delegates at the American Society of Human Genetics Annual Meeting, which is currently occurring in the nation’s capital, most are in possession of some of the information that the Human Variome Project is trying to share. Some have found novel mutations in human genes associated with genetic diseases, others have identified drugs and other compounds that are more, or less, effective in people with certain mutations, and others deal on a day-to-day basis with patients with genetic diseases. What these delegates don’t have however, is the knowledge of how to share that information effectively.
“This is obviously something that needs to change,” says Cotton, “And it’s an area where the Human Variome Project is very active. We held our own meeting this week as a satellite to ASHG that was focussed solely on education.”
But a lack of education about how to share data is not the only challenge facing the Human Variome Project. Some delegates are reluctant to share their data, hoping to protect future research projects. Others are restricted by the intellectual property interests of their employers. “These are valid concerns,” says Cotton, “and I certainly understand them. We are working on a number of ways of minimising them, such as talking to the genetics journals about ways to provide credit and incentives for data sharing. But at the end of the day, we’re talking about data that can help save lives.”
The Human Variome Project sees the sharing of data on genetic variants as a moral imperative and says there are a few things that should be done to help bring about an increase in the amount of information being shared.
The diagnostic testing laboratories that are producing a large proportion of the genetic variation data Cotton says is not being shared are also some of the largest consumers of genetic variation information. The business of these laboratories is genetic testing and providing doctors with an interpretation of the results of those tests. To make these interpretations, these laboratories need access to high quality genetic variant data. If they shared information with the genetic variation research community, it would make their jobs easier and provide new opportunities for medical researchers.
“Government also has a role to play in this,” says Cotton, “by mandating that government funded research and diagnostic labs share data.” Encouragingly, this is already happening, with the NIH recently requiring that grants over $500,000 must address data sharing in their applications. “But,” says Cotton, “a stronger stance needs to be taken on how the data from these projects are shared.” Other countries are already taking a leading position on this. The Human Variome Project recently announced that Australia, Kuwait, Malaysia and China had all initiated projects to systematically collect information on all genetic variation present within their populations.
Finally, individual Americans can make a difference, by requesting that the results of their own genetic tests be made available to the research and diagnostic community. The data shared is not able to be traced back to individuals but can make a difference to people suffering from genetic diseases all over the world.

More than ever we are living in a world where our individual genetic makeup will determine the course of any medical treatment we may undergo. We will all be the eventual recipient of possibly life altering medical intervention that is based on the insights gleaned from the unique genetic sequence of somebody else. Without the free and open sharing of information on genetic
variations, we are essentially withholding treatment from people who are already suffering.

Qualitative mammary cancer susceptibilities Genes are ATM, BRCA1, and p53,p63 TSGs

Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Breast Cancer Use of Science in Treatment Decision-Making FDA Tool

2010-10-28T22:11:00.000-07:00

October 29, 2010 By Robert Graham -- Bethesda Marriott Conference Center

Joshua Sharfstein, MD, of the FDA Today at the Mid-Atlantic BIO Conference spoke about FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making Recommendations focus on innovation, regulatory predictability, and patient safety

Hybrid Pharma Panoincell qX CIO says that Assessment of the 510(K) will help Hybrid Pharma Panoincell qX.

Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53,p63 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency’s public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

The FDA’s Center for Devices and Radiological Health assessment consists of two preliminary reports. One report focuses on ways to strengthen and clarify a premarket review process called the 510(k) program for medical devices that do not need to undergo a full premarket approval review. The other evaluates CDRH’s use of science in decision-making, with an eye toward adapting to new scientific information, while maintaining regulatory predictability necessary for innovation.

The two documents overlap in several places and cross-reference information. The documents can be found online.

CDRH established two staff committees on these issues in late 2009 as part of its 2010 strategic plan. The committees collected and reviewed input from public meetings, open dockets, data analyses, and input from CDRH staff over the course of several months to prepare the complementary evaluations.

In recent years, concerns have been raised both inside and outside of the FDA about whether the current 510(k) program achieves its goals of making safe and effective devices available to the public while fostering innovation. Concerns about the program have centered on whether it allows devices to enter the market without sufficient safety and effectiveness evidence and whether a lack of predictability, consistency, and transparency is hindering device development.

CDRH uses science to guide its regulation of medical devices across the total product lifecycle. At any stage of that lifecycle, new, unfamiliar or unexpected scientific information may arise that warrants a change in the FDA’s thinking, expectations, and actions. CDRH is seeking to strike the right balance between the ability to adapt its approach as new science emerges and to provide predictable regulatory pathways.

“Taken together, these preliminary reports show a smarter FDA – an agency that recognizes both sides of our mission to protect and promote public health,” said CDRH Director Jeffrey Shuren, M.D. “The agency is ready to make necessary improvements to support device innovation while assuring patients receive safe and effective devices.

“Even with our significant outreach, it’s important to remember that these recommendations are preliminary,” said Shuren. “CDRH opened another public docket to receive additional comments on both reports. We will make a decision on which recommendations to adopt only after a thorough review of additional comments.”

Selected recommendations and the key public health objectives they address include:

Fostering Device Innovation

* The 510(k) report recommends major improvements to the regulatory pathway for lower-risk novel devices that cannot be cleared through 510(k) but which do not warrant the more rigorous premarket approval review applied to higher-risk devices. The report calls for major reforms in the implementation of this process – called the de novo classification process. The recommendations include streamlining the process and clarification of CDRH’s expectations for submissions that undergo this type of review.
* The science report recommends that CDRH make better use of scientific experts outside of the agency by developing a web-based network of external experts using social media technology. This network would help CDRH staff leverage outside knowledge without serving in an advisory capacity.

Enhancing Regulatory Predictability

* The 510(k) report recommends that CDRH develop a guidance document defining a subset of moderate-risk (Class II) devices, called Class IIb, for which clinical or manufacturing data typically would be necessary to support a substantial equivalence determination. This guidance document would help clarify what information submitters should include in their 510(k) submissions so that they can plan accordingly. In addition, this would also help the center’s review staff obtain the type and level of evidence necessary to make well-supported decisions without as much need for time-consuming follow-up requests for information.
* The science report recommends use of a standardized “Notice to Industry” letter that would generally be issued as a "Level 1 - Immediately in Effect" guidance document to quickly communicate when CDRH has changed its premarket regulatory expectations due to scientific information that has emerged about a certain device type. CDRH currently communicates this kind of information through individual interactions during the review process, which can lead to delays. These letters would provide greater clarity to affected manufacturers, in a timelier manner, about CDRH’s expectations with respect to a particular group of devices.

Improving Patient Safety

* The 510(k) report recommends that CDRH consider revising regulations to explicitly require 510(k) submitters to provide a summary of all scientific information known or that the submitter should reasonably know regarding the safety and effectiveness of the device under review. This is not required now for 510(k) submissions and, as a result, relevant information may not be included in an initial submission. This summary would help CDRH review staff to more efficiently make decisions, and potentially avoid extensive follow-up inquiries and questions.
* The 510(k) report recommends that CDRH develop a guidance document that clarifies when a device should not be used as a predicate, such as when the device has been removed from the market because of safety concerns. The report also recommends that the center consider issuing a regulation that would clarify the circumstances under which the center would exercise its authority to rescind a 510(k) clearance to remove an unsafe device from the market and preclude its use as a predicate and also consider whether additional authority is needed.
* Both reports recommend that CDRH build upon public databases to include meaningful, up-to-date information that supports good decision making and promotes the safe use of devices. This could be accomplished by improving the current 510(k) database so that it includes summaries of FDA review decisions, current labeling and photos. In addition, the science report recommends that CDRH build upon the existing transparency website to provide more immediate information on how devices are regulated.

The p53, p63 and p73 genes is the heart of the war on Breast Cancer

2010-10-23T15:45:00.000-07:00

October 25, 2010 By Robert Graham -- Washington DC /Businesswire/
The p53, p63 and p73 genes is the heart of the war on Breast Cancer.When p53 is suppressed, as it is in many cancers, defective cells multiply, fueling Breast Cancer. p53 can't order a bad cell to kill itself without p63 and p73 also being active.

When metastatic Breast Cancer occurs p63 is inactive.The reactivation of TAp63 could benefit patients with metastatic breast cancer.

Viral transduction of a few genes for the reprogramming of
human somatic cells into induced pluripotent stem (iPS) cells.Identifying conditions that can replace viral transduction of oncogenic transcription factors (TFs) and enhance reprogramming efficiency. Hybrid Pharma have found that neural progenitor cells can be reprogrammed with fewer genetic manipulations than previously reported somatic cells, and in the other we have found
that small molecules may be able to replace viral integration of
certain transcription factors and promote the reprogramming process.

Genomic Science indicates that we have to change the breast cancer culture to find a cure. Stem cells and progenitor cells has shown promise. Like stem cells, progenitor cells have a tendency to differentiate into a specific type of cell. In contrast to stem cells,
however, they are already far more specific: they are pushed to
differentiate into their "target" cell. The most important difference
between stem cells and progenitor cells is that stem cells can
replicate indefinitely, whereas progenitor cells can only divide a
limited number of times. Controversy about the exact definition
remains and the concept is still evolving.

Hybrid Medical first direction of research aims to determine
what cell becomes transformed; in other words, the cell of
origin of a breast tumor. In the mammary gland, mammary stem
cells, which can self-renew and differentiate, generate rapidly
dividing progenitors that in turn generate differentiated cells
of the mammary gland epithelial lineages: the luminal and myoepithelial lineages. Cancer is thought to originate in these stem cells or in progenitor cells that have acquired self-renewal. Thus, a first degree of heterogeneity comes from whether a tumor comes from a stem cell or a progenitor cell.

Hybrid second direction aims to determine what genetic alterations
transform a normal breast cell and make it cancerous. The repertoire of genetic alterations can be found by using high-throughput, large-scale methods, such as mass sequencing and array comparative genomic hybridization (aCGH) . These have
revealed a number of alterations – mutations, deletions,
amplifications and fusions – that target hundreds of genes,
suggesting a high level of heterogeneity. Some tumors can
have a high level of genetic instability whereas others can
have an apparently normal genome.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts.
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53,p63 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

Virtually all risk prediction for breast cancer assumes that breast cancer is a homogeneous disease

2010-10-13T07:01:00.001-07:00

October 14, 2010 By Robert Graham Reporting -- From New York City at NYU /Businesswire/

Hybrid Medical research shows that Virtually all risk prediction
for breast cancer assumes that breast cancer is a homogeneous disease, i.e. all types of breast cancer have the same risk profiles.

Genomic Science indicates that we have to change the breast cancer culture to find a cure. Stem cells and progenitor cells has shown promise. Like stem cells, progenitor cells have a tendency to differentiate into a specific type of cell. In contrast to stem cells, however, they are already far more specific: they are pushed to differentiate into their "target" cell. The most important difference between stem cells and progenitor cells is that stem cells can replicate indefinitely, whereas progenitor cells can only divide a limited number of times. Controversy about the exact definition remains and the concept is still evolving.

Hybrid Medical first direction of research aims to determine what cell becomes transformed; in other words, the cell of origin of a breast tumor. In the mammary gland, mammary stem cells, which can self-renew and differentiate, generate rapidly dividing progenitors that in turn generate differentiated cells of the mammary gland epithelial lineages: the luminal and myoepithelial lineages. Cancer is thought to originate in these stem cells or in progenitor cells that have acquired self-renewal. Thus, a first degree of heterogeneity comes from whether a tumor comes from a stem cell or a progenitor cell.

Hybrid second direction aims to determine what genetic alterations
transform a normal breast cell and make it cancerous. The repertoire of genetic alterations can be found by using high-throughput, large-scale methods, such as mass sequencing and array comparative genomic hybridization (aCGH) . These have
revealed a number of alterations – mutations, deletions,
amplifications and fusions – that target hundreds of genes,
suggesting a high level of heterogeneity. Some tumors can
have a high level of genetic instability whereas others can
have an apparently normal genome.

For an example when monitoring the activities of a protein
created by a gene associated with breast cancer,
called "ABCC11." By studying this gene and its
complex cellular and molecular interactions in
the body, researchers have discovered a distinct
link between the gene and excessively smelly
armpits and wet, sticky earwax.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts Panoincell qX computer-assisted diagnosing of breast cancer from mammograms.

How Panoincell qX works is a genetic network simulation trained
with tumor incidence data from knockout experiments.
The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

Breaking Ground: Improving the Quality of Life for Cancer Patients

2010-10-03T01:32:00.000-07:00

October 04, 2010 By Robert Graham Reporting -- From NIH Washington DC /Businesswire/
Mei R. Fu: A Pioneering Approach to Lymphedema

When Mei R. Fu, RN, PhD, began studying lymphedema, patients received little information on how to treat this common after-effect of breast-cancer treatment or reduce the risk of its occurrence. In fact, Dr. Fu says, it was practically taboo to talk about the condition with patients or to suggest that they had any control over developing it.

Now, Dr. Fu’s groundbreaking research has been credited with starting to change the way the health care system educates patients about controlling this debilitating and feared syndrome. Lymphedema, caused by abnormal accumulation of lymph fluid in the affected areas and arms, leads to persistent and painful swelling, as well as multiple distressing symptoms. It can occur at any time after breast cancer treatment, eventually affecting up to 65 percent of survivors in the United States.

“People used to think that lymphedema was the result of poor surgical techniques and that there was little they could do about it—both of which are untrue,” Dr. Fu says.

In the past 5 to 10 years, there has been growing awareness that lymphedema is a chronic problem that can be controlled and managed. In the past 2 years alone, technology and the availability of information online have significantly changed the attitudes of healthcare providers (including surgeons, oncologists, nurses, physical therapists) and patients.

Dr. Fu’s research, funded by the Avon Foundation, was the first to show that patient education has positive effects on patients’ cognitive-behavioroutcome in lymphedema risk reduction and patients’ symptom outcome, offering patients a major benefit. An abstract, “Lymphedema Education and Risk Reduction in Breast Cancer Survivors,” presented by Dr. Fu with Dr. Judith Haber, Dr. Amber Guth, and Dr. Deborah Axelrod at the Oncology Nursing Society 2008 Annual Congress, was chosen as one of the top 10 highest scoring abstracts among 500 entries, and their manuscript went on to win the Oncology Nursing Society Excellence in Cancer Nursing Research Award in 2009. This study was published in Annals of Surgical Oncology, a prestigious peer-reviewed journal in surgical oncology field and Journal of Nursing Scholarship, a prestigious nursing journal . Dr. Fu has also won the Young Investigator Award from International Lymphology Society for her three qualitative research studies on lymphedema and received the Excellent Service Award from the American Cancer Society for her long committed service and quality speech for cancer patients.]

Based on the findings, Dr. Fu and her research team have developed an intervention called The Optimal You to help patients reduce the risk of lymphedema or improve their symptom experience if they already experience it. With additional funding from Avon, she is testing the intervention with two groups of 120 patients each at the NYU Clinical Cancer Center. The intervention focuses on teaching patients to prevent inflammation and fluid accumulation—the major risk factors—through daily fluid drainage and other symptom-management strategies. The first group is receiving the risk-reduction intervention prior to cancer surgery and is being followed at three intervals after surgery to test its efficacy.
A second group of patients, who already demonstrate lymphedema symptoms, is receiving an intervention to help control their symptoms. This study is the first to focus on fluid drainage and other strategies to manage symptoms. It is also the first to make use of a new, state-of-the-science technology, the perometer, which calculates and tracks very small limb-volume changes, thereby identifying fluid build-up in the arm. The device located at NYU Clinical Cancer Center is one of only several in the country.

“The beauty of this study is that it focuses on risk reduction for people before surgery, so that we can take steps immediately to prevent the onset,” Dr. Fu says.

Is lymphedema still taboo? The culture is changing, according to Dr. Fu, and NYU’s Clinical Cancer Center is leading the way by talking about this difficult syndrome.

The next phase of Dr. Fu’s research involves looking at genetic variations that may put some patients at greater risk for developing lymphedema. She is the principal investigator on a pilot study with colleagues at the University of Pittsburgh, funded by the Pless Center for Nursing Research at the College of Nursing, aiming to explore the effect of r inflammatory genes and those genes related to the lymphatic system.

“We believe that some patients are more prone to inflammation and accumulation of fluid,” Dr. Fu says. “That’s why it’s very important to explore genetic variations, to see who is at greater risk.” Dr. Fu reports that nearly 100% of those patients who have been asked have willingly contributed genetic samples. “This information will give us a clearer idea of how to implement personalized care for those patients who are at greater risk,” she says.

For those patients who have developed lymphedema, Dr. Fu is collaborating with physical therapists at NYU Rusk Rehabilitaiton Center Physical Therapy Department to offer an innovative approach to treat this chronic condition by testing the effectiveness of low level laser therapy through a double-blind, randomized, placebo-controlled study.

Dr. Fu’s collaborators include nationally well-known breast surgeons at NYU Cancer Center, Dr. Deborah Axelrod and Dr. Amber A. Guth; Nurse Scientist, Dr. Francis Cartwright; nationally well-known geneticist, Dr. Yvette Conley at University of Pittsburgh; Physical therapists, Teresa V. Denham PT, MA and Ting Ting Kuo PT,DPT,WCS,CLT at NYU Rusk Rehabilitaiton Center Physical Therapy.
Dr. Fu also serves on the Board of Directors for the Lymphology of North American Association, the Medical Advisory Committee of the National Lymphedema Network, where she has co-chaired the research committee. She serves on the Steering Committee for the American Lymphedema Framework Project, a national partnership with the International Lymphedema Framework (ILF), where she has co-chaired the research and dissemination committee. She also serves as the Editorial Director and the Research Director for Stepup-speakout Organization, a patient advocacy organization to promote lymphedema research, education, and practice. She is on Education Advisory Panel and the Editor for Lymphedema Management Special Interest group for Oncology Nursing Society. In addition, she is also on the editorial board for several peer-reviewed journals, including Advances in Nursing Science, Austral-Asian Journal of Cancer: The International Cancer Journal of Australia and Asia, and Journal of Lymphedema.

Is Invasive Breast Cancer is too High in Black Women

2010-09-25T03:23:00.000-07:00

September 25, 2010 By Robert Graham -- Washington DC /Businesswire/

Hybrid Pharma scientist: Invasive breast cancer is the most frequently diagnosed
new malignancy.Breast cancer continues to exact a major toll in the US: it
is the most frequently diagnosed cancer in women and the
second leading cause of cancer mortality.
This malignancy currently accounts for 32% of all new
cancer cases and 15% of cancer deaths among American
women Incidence rates in the Hybrid Pharma
database vary greatly by race and ethnic group, with
lower rates seen for black, Asian, and Hispanic women
than for white women. Although breast cancer incidence
rates have been increasing since the 1980s, death rates
have declined by about 2.3% per year since 1990
with some of the downturn related to increases in early
detection by mammography and to effective treatment with
adjuvant chemotherapy .About 72% of the invasive breast cancers
reported to Hybrid Pharma are ductal carcinomas, not otherwise
specified (NOS); 9% are lobular carcinomas; and the
remaining 19% are other histologic types. The current relative
survival rates for all breast cancers combined are
88.8% at 5 years (79.5% at 10 years) for white females,
but only 75.3% at 5 years (63.9% at 10 years) for black
females.

Breast cancer analytics one million diagnoses a year worldwide
(200,000 in the US); 40,000 deaths per year; one-fifth of all
deaths in womenaged 40-50; $60-$100 billion in direct and
indirect costs every year.

Treatment for early-stage invasive breast cancer
shifted in the 1980s and 1990s from radical mastectomy
with or without regional radiotherapy to the chest wall
and lymph nodes (post-mastectomy radiation) to increasing
use of breast-conserving surgery followed by breast
radiation (post-lumpectomy radiation). Adjuvant chemotherapy (including
alkylating agents) and hormones (tamoxifen) are also
widely used. With the one million diagnoses a year worldwide
(200,000 in the US); 40,000 deaths per year; one-fifth of all deaths in women
aged 40-50; $60-$100 billion in direct and indirect costs every year.

Hybrid Pharma research about cancer enable us to fight
Breast Cancer. We know that it is characterized by genomic instability-tumor
cells divide like mad and in that process their genomes are
rarely transmitted faithfully. Breast cancer is no exception:
any ten women with the disease will have ten different tumors-their
cancers will be of different sizes, some will be more aggressive
than others, and those tumors will each express their own peculiar
set of genes (albeit with some overlap). At Duke, genome scientists
and clinicians have begun to make use of breast cancer' s
heterogeneity to make predictions and guide treatment decisions.
By examining the expression patterns of collections of genes that
tend to be turned off or on together in an array of tumor samples
and the clinical outcomes of patients who developed those tumors,
Hybrid researchers are now able to predict who is most likely to experience
recurrent breast cancer and who is likely to remain cancer-free.
This information has practical implications. If her risk is low,
a patient may not want to endure the hardships of chemotherapy;
if her risk is high, she may choose a more aggressive course of
treatment.

Hybrid Pharma study to show that results from this
test simultaneously impact decisions by physicians as
well as patients.

For an example when monitoring the activities of a protein
created by a gene associated with breast cancer,
called "ABCC11." By studying this gene and its
complex cellular and molecular interactions in
the body, researchers have discovered a distinct
link between the gene and excessively smelly
armpits and wet, sticky earwax.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms.

How Panoincell qX works is a genetic network simulation trained
with tumor incidence data from knockout experiments.
The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

The new trend in oncology is towards personalized medicine

2010-09-10T23:35:00.000-07:00

September 11, 2010 By Robert Graham -- Washington DC /Businesswire/

Washington,DC September 11 : A new study shows that a 21-gene
test of a patient's breast cancer tumour may change
doctor and patient treatment decisions, including
the need for chemotherapy.

Hybrid Pharma test, Panoincell qX, is made by Hybrid Pharma Inc.
which examines 21 genes from a tumour sample to determine
how active they are.

A test score between 0 and 50 predicts how likely the
cancer is to recur. For women with low scores, chemotherapy
is not recommended.

More than 130,000 breast cancer patients have undergone
the test since it became commercially available.

The test is intended for patients who have a type of
breast cancer, called estrogen receptor-positive, which
has not spread to the lymph nodes. About 110,000 such
cases are diagnosed each year.

The trend in oncology is towards personalized medicine.
We likely will see more tests similar to this one in the
future," said Loyola University Health System Medical
oncologist and study's lead author Dr. Shelly Lo.

The findings are based on study, which included 89
breast cancer patients who received the gene test.

They were treated by 17 medical oncologists at Loyola,
University of Michigan, University of California at Davis
and Edward Hospital in Naperville, Il.

Doctors changed treatment decisions for 28 patients.
In 20 of these cases, they changed their decision from
hormone therapy plus chemotherapy to hormone therapy alone.
24 patients changed their treatment decisions, including
nine who dropped chemotherapy.

Hybrid Pharma study to show that results from this
test simultaneously impact decisions by physicians as
well as patients.

For an example when monitoring the activities of a protein
created by a gene associated with breast cancer,
called "ABCC11." By studying this gene and its
complex cellular and molecular interactions in
the body, researchers have discovered a distinct
link between the gene and excessively smelly
armpits and wet, sticky earwax.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms.

How Panoincell qX works is a genetic network simulation trained
with tumor incidence data from knockout experiments.
The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

Hybrid Pharma Today announced that Erin Azar has joined the company as VP of Worldwide Marketing

2010-08-26T07:32:00.000-07:00

Houston TX – August 26, 2010 –– (BUSINESS WIRE)------ Hybrid Pharmaceutical, the Genomics Biotech Engineering company, today announced that Erin Azar has joined the company as vice president of worldwide marketing. In her new role, Azar oversees the strategic management of global marketing initiatives for Hybrid Pharma®. Azar brings more than 20 years of experience in marketing management with expertise in developing and managing go-to-market strategies and initiatives, brand management, channel marketing and enablement, lead generation and field marketing.
The Hybrid Pharmaceutical Integrated Clinical Research Suite (HPIC) offers a global, integrated set of solutions to help life sciences companies of all types and sizes manage their entire clinical development process — from Phase I through regulatory submission, post-approval trials and pharmacovigilance. With the ICRS, organizations can rely on a single solution provider to help them meet drug development needs in today’s challenging environment.. As Hybrid Pharma looks to extend its leadership in Biotech Engineering to new products and markets, including cloud storage, Azar is leading the effort to communicate the company’s vision and strategy and to develop and implement go-to-market activities. Additionally, Azar is responsible for extending Hybrid Pharma’s brand equity and accelerating growth with its partners through Hybrid Pharma partner program enablement and recruitment initiatives.
“Erins’s proven ability to develop expansion strategies in new and existing market segments will enable her to align Hybrid Pharma marketing efforts for the company’s next round of growth,” said Elizabeth Jones, senior vice president, marketing and business development at Hybrid Pharma. “We look forward to enhancing our overall brand and market leadership position worldwide with Erins’s direction and collective experience in sales, marketing and communications.”
Prior to joining Hybrid Pharma, Azar was senior vice president of worldwide marketing at MNM BRAND STREET, where she oversaw all outbound marketing strategy components, including company branding and communications, product marketing, the company’s partner program, and the management of all aspects of online and offline demand generation. Prior to MNM, Azar was Digital Marketing Director at GREY WORLDWIDE/G2, where she architected and implemented the company’s systems integrators go-to-market strategy.
“With the increasing adoption of consolidation, virtualization, and cloud-based services, there is a bright future ahead for Hybrid Pharma,” said Azar. “I look forward to leading the effort to expand the market opportunities for Hybrid Pharma products and building go-to-market strategies that enable organizations to realize optimal IT performance.”
Forward Looking Statements
This press release contains forward-looking statements, including statements relating to the expected demand for Hybrid Pharma's products and services, statements regarding Hybrid Pharma’s growth and market opportunities, and statements relating to Hybrid Pharma’s ability to meet the needs of distributed organizations. These forward-looking statements involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Hybrid Pharma reserves the right to modify future product plans at any time.
About Hybrid Pharma
Hybrid Pharma is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services is available at www.Hybrid Pharma.com.

64% Reduction in Chronic Disease Health Care costs with Hybrid Medical IntraMed’s Patient Monitoring Solution

2010-08-19T04:26:00.000-07:00

August 19, 2010 By Erin Azar -- Washington DC /News----wire/ --
64% Reduction in Chronic Disease Health Care costs with Hybrid Medical IntraMed’s Patient Monitoring Solution

Hybrid Medical introduces IntraMed’s CSO (Clinical System Organizer) product suite, a comprehensive web-based software solution, providing more effective and efficient care for a full range of chronic diseases. Through careful tracking of patients’ disease information, physicians are able to more accurately manage chronic illnesses and identify concerning trends at the early stages, ensuring corrective action at the right time. In partnership with President Obama’s broadband stimulus initiative, Hybrid Medical aims to provide all patients, rural and urban, with convenient access to top quality care.

Broadband and 4G/LTE enabled health telemonitoring products allow physicians to track patients’ heart disease and diabetes vitals, providing high quality care to rural areas. Cardiac arrests in rural areas are expected to decline by 28%, as a result of IntraMed’s smart tracking products.

With over a decade of proven market adoption, IntraMed’s CSO supports more than 50% of all cardiac and diabetes patients in Denmark. The Medical Center of Plano, Texas, currently uses CSO/Anticoagulation to improve the quality and efficiency of their medical care. The CSO products’ easy and robust software is embraced worldwide, and has set the international standards in chronic disease management.

“We are extremely excited to bring this new capability to the US market. We are confident this will immediately impact the market, and deliver to the real challenges of our physicians,” said Dr. Robert Graham, CIO, Hybrid Medical.

Denmark’s use of smart technologies throughout its healthcare system has drawn the attention of President Obama’s administration. Ninety-nine percent of all doctors in Denmark are connected through Broadband access and Electronic Medical Records are a national mandate in Denmark. The progressive healthcare system in Denmark demands innovative solutions.

About IntraMed
IntraMed is a Danish owned company with headquarters in Denmark. Since its launch in 1997, IntraMed has developed IT products aimed at supporting more effective treatment of the chronically ill.

About Hybrid Medical
Since 1987, Hybrid Medicall has been a leader in Genomic trials, healthcare IT, and life sciences clinical development solutions. Hybrid Medical is headquartered in Houston, Texas.

Hybrid Medical Analytics Inc. today announced the release of its OpenLAB Electronic Lab Notebook

2010-08-11T04:26:00.000-07:00

Houston, Texas., Aug. 11, 2010 /News----wire/ --

Hybrid Medical Analytics Inc. today announced the release of its OpenLAB Electronic Lab Notebook (ELN) version 5.1. The new version offers scientists in analytical research and development an optimized way to document and share experiments and results. CSO (Clinical System Organizer) is a web-based system, which improves treatment quality and streamlines processes for the benefit of the economy in health care. CSO has specific modules aimed at a number of major chronic diseases.

CSO sharing clinical data between the actors involved in the clinical process. It is a user-friendly system, developed in collaboration with doctors who have special insight into chronic diseases. It can be used by both clinicians and patients.

OpenLAB ELN v5.1 introduces experimental templates that enable scientists to create, share and reuse their own custom API experiment views. The new flexible templates facilitate data entry by allowing scientists to view the experiment desktop as they prefer. These templates can be designed for SOP-driven processes,
increasing laboratory efficiencies.

Hybrid has also streamlined the analytical request workflow by reducing the number of steps between request and result. This dramatically improves lab productivity. A specific analytical module has been added for documenting analytical methods, generating sequence files and capturing results. The new module
facilitates report creation across one or more samples and Hybrid Medical techniques. Chromatograms and result files from Hybrids Sybase RAP IQ 4 #Software, or other chromatography data systems (CDS) can be automatically uploaded and associated with the experiment through the seamless integration with Hybrid Medical OpenLAB ECM scientific data management system. Hybrid offers the complete solution.

In addition, the new delegation workflow facilitates collaboration. Multiple scientists can collaborate on a single experiment, enter data and results from multiple techniques on a single sample or multiple samples. Audit trails are maintained in an environment that
delivers the highest level of intellectual property protection.

"Ideally, software helps people be more productive with very little additional thought or effort," said Donald Lee, vice president and general manager, Hybrid Medical Analytics and Informatics. "This is the motivation behind the entire Hybrid Medical OpenLAB portfolio of laboratory systems."

OpenLAB ELN is a Web-based scalable, integrated system to manage experiments and results. It is designed for multiple disciplines including analytical chemistry, synthetic/medicinal chemistry, biology and other research environments. OpenLAB
ELN supports 21 CFR Part 11 requirements and is built around an RedHats open architecture

Hybrid Medical International OpenLab new location is located in Tyson Corner, Virgina

The number one legislation for Breast Cancer Patients is HR 5440:

2010-08-06T07:51:00.000-07:00

August 6, 2010 By Robert Graham -- The number one legislation for Breast Cancer Patients is HR 5440: Genomics and Personalized Medicine Act of 2010 sponsored by Rep. Patrick Kennedy [D-RI1]

HR 5440 purpose is to secure the promise of personalized medicine for all Americans by expanding and accelerating genomics research and initiatives to improve the accuracy of disease diagnosis, increase the safety of drugs, and identify novel treatments, and for other purposes.

Hybrid Medical Analytics mission is to enhance understanding of the molecular mechanisms of cancer, with the ultimate goal of improving the prevention, early detection, diagnosis, and treatment of breast cancer.

Genomic Science determine which genes are expressed at different levels in tumors compared to normal cells or how the chromosomes are rearranged and their throughput; further decreasing the costs of DNA sequencing; improving the detection of epigenetic changes; and developing new analytical methods to correlate disease state with the intricate network of molecular
interactions in a cancer.

Genomics will accelerate Breast Cancer treatment in rural America using informatics technologies Microsoft Windows 7, Broad Band, Sybase, Cloud Computing Services and Tele-Medicine technologies along with HR5440 will extend Breast Cancer patients lives.

The single greatest Breast Cancer risk factor

2010-07-24T00:29:00.000-07:00

JULY 24, 2010 By Robert Graham -- Washington, DC

The single greatest Breast Cancer risk factor is a family history of the disease.
Autosomal dominant inheritance of breast cancer is characterized by
transmission of cancer predisposition from generation to generation,
With the Increased use of preoperative MRI may play a role, but mastectomy rates also
rose in women not undergoing preoperative MRI.Mastectomy rates
have been on the upswing at the Mayo Clinic in Rochester, Minnesota,
and researchers cited MRI as a factor influencing the increase.

Inheritance risk of 50%. When a parent carries an autosomal dominant genetic
predisposition, each child has a 50:50 chance of inheriting the predisposition.

Both males and females can inherit and transmit an autosomal dominant
cancer predisposition. A male who inherits a cancer predisposition and shows
no evidence of it can still pass the altered gene on to his sons and daughters

One of the ways to be sure that a Mastectomy is the way to go is genomics
Genomics is the study of the human cancer genome. It is a search within
"cancer families" and patients for the full collection of genes and
mutations--both inherited and sporadic--that contribute to the development
of a cancer cell and its progression from a localized cancer to one that grows
uncontrolled and metastasizes (spreads throughout the body).

To Educate Oncologist and Breast Cancer Patients and in rural areas,is to incorporate
TeleMedicine using Wireless BroadBand Spectrum that President Obama has given the FCC
the okay allocate to customers in Rural areas. Others technologies will help Breast Cancer
Patients Make better treatment choices is listed below

Cloud computing:

Worldwide revenue from public IT cloud services exceeded $16 billion in 2009

Software as a Service:

SaaS = 73% of public Cloud services revenue in 2009
Forecasted to reach $55.5B in 2014, with a CAGR of 27.4%
Public IT cloud will be over 25% of the net-new growth in traditional IT
products between now and 2014.

It is clear to Hybrid Medical Analytics that we can help Oncologist help their Breast
Cancer Patients.

PRESIDENT CLINTON ANNOUNCES HUMAN GENOME June 26, 2000

2010-07-12T22:52:00.000-07:00

JULY 14, 2010 By Robert Graham --
PRESIDENT CLINTON ANNOUNCES THE COMPLETION OF THE FIRST

SURVEY OF THE ENTIRE HUMAN GENOME Hails Public and Private Efforts Leading to This Historic Achievement
June 26, 2000

A historic White House event with British Prime Minister Tony
Blair, President Clinton announced that the international Human Genome Project and Celera Genomics Corporation have both completed an initial sequencing of the human genome -- the genetic blueprint for human beings.

Genomics Science and Broad Band will Reduce Breast Cancer in Rural Areas After H.R.5440: Genomics and Personalized Medicine Act of 2010 - U.S passes.

JULY 2, 2010 U.S. President Barack Obama announce new American Recovery and Reinvestment Act broad band projects.

July 12th 2010 Steve Ballmer outlined how cloud computing is
transforming IT. Bob Muglia announced the Windows Azure Appliance. Tami Reller detailed the partner opportunity with Windows 7.

July 14 2010 Hybrid Medical Analytic CIO -Microsoft Can Help President Obama Create 100,000 Jobs in Rural Areas with Microsoft's Partner Program .

Today's Microsoft is equip to Assist Small Business grow with several New Programs like Microsoft New Certification.

The Ingredients is there to put America's High Tech Workers back
to Work. Retrained in Bio Tech Engineering.

Microsoft is showing that their Preoccupations and Obsessions of being the Best in the world is on Display at The Microsoft Worldwide Partner Conference 2010 held on July 11-15, 2010, at the Walter E. Washington Convention Center, Washington D.C., USA.Thefive-day partner event of the year offers you the opportunity to learn about Microsoft's roadmap and best
practices for the year. You will gain exclusive access to
networking with Microsoft executives and other partners.
You will explore the infinite opportunities with Microsoft's
cloud computing strategy to take your business to the next
level and gain an edge on your competition.

Mircosoft Partners are as strong as they have ever been, Hybrid
Medical has Named this years "Best of show" to iLink System From
Remond,WA. Take a Look at the Video to See Why.

Microsoft has Named Slalom Consulting Seattle, WA as Partner
of the Year. Take Look at this Video of Slalom at their Party
at Long View Gallaery in Washington DC.

Hybrid Medical Analytics has identified The Vertical Market that
Partners can use to grown their Partnerships. Health Care It combine with Genomics, Personalized Medicines, President Obama Broad Band for Rural Areas and Sharepoint can create over 100,000 Jobs in Rural America.

The WPC 2010 EXPO includes:

The newest products and services from Microsoft, including
Windows 7 and Office 2010.
The latest information about Cloud Services - build
solutions in the Cloud to bring businesses online.
Experts demonstrating the latest and greatest
in end-to-end solutions for the IT sector.
Presentations at the Expo Theater Live Stage.

Over 100 interactive sessions and over 170 Exhibitions.

If you are in IT and is not Here you are missing The Best in the World

Regenerative medicine company that uses induced pluripotent stem (iPS) cells, has raised $22 million.

2010-07-09T07:24:00.001-07:00

JULY 10, 2010 By Robert Graham -- Regenerative medicine
company that uses induced pluripotent stem (iPS) cells, has
raised $22 million.

Hybrid Medical Analytics Research has shown genomics, pluripotent stem (iPS) cells is the Future for Treating Breast Cancer along with Bacteria process called quorum sensing.

Bacteria communicate with one another using chemical signal
molecules. As in higher organisms, the information supplied by these molecules is critical for synchronizing the activities of large groups of cells. In bacteria, chemical communication involves producing, releasing,detecting, and responding to small hormone-like molecules termed autoinducers. This process, termed quorum sensing, allows bacteria to monitor the environment for other bacteria and to alter behavior on a population-wide scale in response to changes in the number and/or species present in a community. Most quorumsensing-
controlled processes are unproductive when undertaken by
an individual bacterium acting alone but become beneficial when carried out simultaneously by a large number of cells. Thus, quorum sensing confuses the distinction between prokaryotes and eukaryotes because it enables bacteria to act as multicellular organisms. This review focuses on the architectures of bacterial chemical communication networks; how chemical information is integrated, processed, and transduced to control gene expression; how intra- and interspecies cell-cell communication is ccomplished; and the intriguing possibility of prokaryote-eukaryote cross-communication.

Regenerative medicine company that uses induced pluripotent
stem (iPS) cells, has raised $22 million in Series B funding. Google Ventures led the round, and was joined by Mitsubishi UFJ Capital, ATEL Ventures and return backers MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases,” said Dr. Yeshwant. ”The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will ramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission.”

Hybrid Medical Analytics has been and will be a Leader in this space.

H.R. 5440, The Genomics and Personalized Medicine Act of 2010

2010-06-26T07:16:00.001-07:00

H.R. 5440, The Genomics and Personalized Medicine Act of 2010

H.R. 5440 would secure the promise of personalized medicine for
all Americans by expanding and accelerating genomics research and
initiatives to improve the accuracy of disease diagnosis, increase
the safety of drugs, and identify novel treatments.
Hybrid Pharmaceutical has just returned from Israel for the Personalized Medicine world Conference
Conference and Discover that the 111th Congress has a Genomics personalized medicine
Bll. This is super great news for Breast Cancer Patients

SEC. 301. GENOMICS AND PERSONALIZED MEDICINE EDUCATION AND TRAINING.

(a) In General- The Secretary shall make grants, contracts, or cooperative
agreements to eligible entities to improve the adequacy of genomics and personalized
medicine training for specimen collection, diagnosis, treatment, and counseling of
adults and children for both rare and common disorders, through support of efforts to--

(1) develop and disseminate model education and training programs across
all health professionals, including medical student, graduate medical, and continuing
education, that reflect the new knowledge and evolving practice of genetics and genomics
including the appropriate use of products used in personalized medicine;

(2) assist with the review of board and other certifying examinations
by professional societies and accreditation bodies to ensure adequate focus on the
fundamental principles of genomics and personalized medicine and applications to
clinical decisionmaking;

(3) identify, evaluate, and develop options for distance or online learning
for degree or continuing education programs;

(4) identify gaps and opportunities to strengthen continuing
education programs for health care professionals;

(5) develop and disseminate model programs to train pathologists
on the specialized mechanisms of collection and storage of human biological
specimens for biobanks; and

(6) develop exchange programs for student, residents, and fellows
to learn techniques and practices to augment genomics and personalized medicine.

SEC. 401. REDUCING THE REDUNDANCY OF CLINICAL LABORATORY REQUIREMENTS.

(a) In General- The Secretary, acting through the Administrator of the Centers
for Medicare & Medicaid Services and the Commissioner of Food and Drugs, shall establish
a committee to carry out a comparative analysis of laboratory review requirements under
CLIA to--

(1) assess and reduce unnecessary differences in such requirements; and

(2) identify opportunities to eliminate redundancies and decrease the burden

of review, as practicable, of the Centers for Medicare & Medicaid Services, the Food
and Drug Administration, and private laboratory certifying entities.

(b) Representation- The membership of the committee established under
this section shall include representatives of the agencies of the Public Health
Service, other appropriate Federal departments and agencies, private laboratories,
and private laboratory accreditation organizations.

(c) Public Input- The Secretary shall conduct open public meetings and
develop a process to allow for public comment on such comparative analysis.

The Food and Drug Administration is issuing regulatory letters for Genomic Test

2010-06-13T05:04:00.000-07:00

WASHINGTON -- 46th DIA (Drug Information Association) Annual Meeting -- The Food and Drug Administration is regulatory letters for Genomic Test. This is the first sign that the government is recognizing companies like Hybrid Pharmaceutical Inc that use DNA samples to predict Breast Cancer and inheritable diseases.

The FDA letters state that genomics tests are considered
medical devices and must be federally approved as safe
and effective.This is great news for Hybrid Pharmaceuticals
and the nascent personal genomics industry and our customers.

Washington DC has the highest Stage IV Breast Cancer Rate
in the US. A genomic test looks looks at 21 genes in a
patient's breast tumor and how active they are. Our focus is
on Genomic Trials. Genomics Science looks at groups of genes
and how active they are. This activity can influence how
a cancer is likely to grow and respond to treatment. Unlike
a genetic test, that provide information about a person’s
inherited genetic make-up. Instead,Hybrid Pharmaceuticals
looks at 21 genes in a patient’s breast tumor trials to
understand how these genes interact and influence the tumor’s
behavior.

85% of Breast Cancer Patients that get a Genomics Personalized
test will enable Oncologist to recommend that right treatment.
instead of the 50% of Breast Cancer Patients that get Toxic
Chemotherapy.

BR Graham Editor

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics

2010-05-28T11:31:00.000-07:00

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics being added to The Veterans Affairs New VISTA S.O.A stratergy.

Scott Cragg, Special Assistant to the CIO, U.S. Department of Veterans Affairs and his Team.
John Teeter, Deputy Chief Information Officer, Department of Health and Human Services. CAPT Michael Weiner, Chief Medical Officer for the Defense Health Information Management System (DHIMS) Ed Meagher, Director, Strategic Healthcare Initiatives, SRA International; former Deputy Chief Information Officer, Dept. of Veterans Affairs (moderator) made their comments at the
AFFIRM The Association for Federal Information Resources Management ( http://affirm.org/ )May Monthly Luncheon on Health IT

The Department of Veterans affirs has a new System Called Veterans Health Information Systems and Technology Architecture (VISTA) said that they are not Including Genomics as a part of their VISTA system.

Genomics is the study of complex sets of genes, how they are expressed in cells (what their level of activity is), and the role they play in biology. Another way to think about it is as a small network of genes and how they work together to influence the a Veterans Breast CancerTumor's biology and behavior.

VISTA is built on a client-server architecture, which ties together workstations and personal computers with graphical user interfaces at Veterans Health Administration (VHA) facilities, as well as software developed by local medical facility staff. VISTA also includes the links that allow commercial off-the-shelf software and products to be used with existing and future
technologies. The Decision Support System (DSS) and other national databases that might be derived from locally generated data lie outside the scope of VISTA.

Hybrid Medical Analytics Our focus is on Genomic Trials. Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment. Unlike a genetic test, that provide information about a person's inherited genetic make-up. Instead,

Hybrid Medical Analytics looks at 21 genes in a patient's breast tumor trials to understand how these genes interact and influence the tumor's behavior.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Electronic e-Clinicals and early stage trials that allows
us unique insight into the most prevalent challenges at this phase of
testing. We have strategically built an infrastructure, methodology
and facility that meet those needs.

82% Increase in Transgenic R&D for Breast Cancer that is Carcinogenesis caused by Li-Fraumeni Syndrome

2010-05-22T07:17:00.000-07:00

82% Increase in Transgenic R&D for Breast Cancer that is carcinogenesis caused by Li-Fraumeni syndrome. Hybrid Medical focused on:

Family history and other risk factors for breast Cancer.
Models for predicting breast cancer risk.
Major genes associated with breast cancer
Screening and risk modification for hereditary breast cancer
Psychosocial issues associated with hereditary breast cancer

Among women, breast cancer is the most commonly diagnosed cancer after nonmelanoma skin cancer.

The syndromes most strongly associated with Breast cancers are BRCA1 or BRCA2 mutation syndromes. Breast cancer is also a common feature of Li-Fraumeni syndrome due to P53 mutations.

Breast Cancer research for a cure has a new friend. P53 or mP53. Mutant in transgenic mice has shown promise in the cure for Breast Cancer. Hybrid Medical e-Clinical generated transgenic
mice carrying mutant p53. We cloned the m53 cDNA from a radiation-induced mouse tumor.

The tumors was treated via a potent atelocollagen suppression of the tumors growth. The Result that mp53 activity caused tumors that can be suppressed by subsequent silencing of the mp53.

This is great news because if you get a Genomics Test and discover that you have Brac1 or Brac2one of the major causes of Breast Cancer, the mP53 Mutant can be suppressed and extend Life

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Pluripotent Stem Cells & Neurotransmitter is a Breast Cancer Game changer for pain.

2010-04-30T23:20:00.000-07:00

Pluripotent Stem Cells & Neurotransmitter is a Breast Cancer Game changer for pain.

Hybrid Medical Analytics research focuses on identifying the cause of chronic pain an ion pump dysfunction in the nervous system that disrupts neurotransmitter signaling.

Breast Cancer pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, Breast Cancer pain can be managed effectively through relatively simple means in up to 90% of Breast Cancer Patients.

Identifying the etiology of pain is important to its management.

Neurotransmitters is showing Promise. billions of neurons in the mammalian brain communicate with each other with liberating chemical messengers that are detected by receptors on adjacent cells.

These chemical messengers, or neurotransmitters, can be ions, amino acids, amino acid derivatives, or large polypeptides.

Gene targeting in embryonic stem cells to generate dopamine-deficient .
Gene targeting in embryonic Pluripotent Stem Cell can be the अन्स्वेर

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Diagnosed with Breast Cancer Analytics eNotebook CIO Reports a 47% Increase in Ex Vivo Activation

2010-04-17T06:46:00.000-07:00

Diagnosed with Breast Cancer Hybrid Medical Analytics eNotebook CIO Reports a 47% Increase in Ex Vivo Activation of Peripheral Stem cell. Hematopoietic or blood stem cell transplants are also
called bone marrow transplants.

Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or
radiation therapy. There are three types of transplants:

In autologous transplants,is where Breast Cancer patients receive their own stem cells.

In syngeneic transplants,is where patients receive stem cells from a identical twin.

In allogeneic transplants, patients receive stem cells from their brother, sister, or parent.

A person who is not related to the patient (an unrelated donor) also may be used.

Hybrid Medical Analytics is a leader in unrelated donor Stem Cells
The primary use for BMT and PBSCT is to minimize any damage to blood stem cells from Breast Cancer treatment, these stem cells from the bone marrow are removed and preserved before patients receive chemotherapy.
The stem cells are then re-infused into the patient after chemotherapy where they migrate to the bone marrow and begin producing new blood cells.

After the stem cell transplantationentering the bloodstream, the stem cells travel to the bone marrow, where they begin to produce new white blood cells, red blood cells, and platelets in a process known as “engraftment.” Engraftment usually occurs within about 2 to 4 weeks after transplantation.
Doctors monitor it by checking blood counts on a frequent basis. Complete recovery of immune function takes much longer, however—up to several months for autologous transplant recipients
and 1 to 2 years for patients receiving allogeneic or syngeneic transplants. Doctors evaluate the results of various blood tests to confirm that new blood cells are being produced and that
the cancer has not returned. Bone marrow aspiration (the removal of a small sample of bone marrow through a needle for examination under a microscope) can also help doctors determine
how well the new marrow is working.

If you have a relative that can not find a Stem Cell match contact Hybrid Medical Analytics Inc

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Breast Cancer happens when changes occur in Your DNA

2010-04-02T23:34:00.001-07:00

Breast Cancer happens when changes occur in your DNA Your Genes Proteins are not made correctly. A protein may be missing, overproduced, shortened, or assembled with alterations.

We know that Breast Cancer arises when a cell undergoes several molecular changes. These changes can take place over many years, and only when the cell has accumulated a critical number of these changes will become a "cancerous" cells.

At Hybrid Medical Analytics our focus is Genomic Science. Genomic Science studies how each organism has its own unique genome. A human genome has 22 pairs of chromosomes and a pair of sex chromosomes.

The human genome has 25,000 genes spread across all 23 pairs of human chromosomes. When a gene "switches on," it eventually makes a protein and thus Breast Cancer

Genomic converts the gene codes an intermediary molecule called mRNA, this transfer a gene's information from DNA to mRNA which allows us to distinguish mRNA from DNA. Using Hybrid Medical informatics scientist can recommend the proper therapy for treating Breast cancer and extend the life of a Breast Cancer patient

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical It is a New Day in Breast Cancer Treatment

2010-03-06T07:26:00.000-08:00

Hybrid Medical Analytics it is a New Day in Breast Cancer.

The question is which targeted Breast Cancer Therapy is best for a individual Patients. Is Genomics the Anwser ?

Hybrid Medical Analytics CIO Reports when Researchers sequence the genomes of 14 triple-negative breast cancer patients with tumors that have progressed despite multiple therapies Breast Cancer patients have a new way to extend life.

The triple-negative tumors make up nearly 20% of breast cancers and do not respond to standard targeted therapies.

In Hybrid Medical Partners Clinical Trials Scientist study both Tumors and Healthy Tissue Sequenced. Then Scientists collaborate on the development using informatics from Hybrid Medical Analytics software that is used with whole genome sequencing. What Scientist in clinical trials Attempt to show how one new drug can be safe and effective for hundreds of people.

Hybrid Medical eLab Notebooks Genomics uses sequencing data from one individual to evaluate which anticancer drugs could be most effective based on normal and tumor genetic makeup

Our Clinical Trial Partners are showing a 80% effective rate using the Genomics Science approach

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

15 % of Black Women to 7 % of White Women are diagnosed with Breast Cancer. Can Genomics be the Tool to low the rate in which black women are dia

2010-02-13T05:36:00.000-08:00

15 percent of Black Women to 7 percent of White Women are diagnosed with Breast Cancer. Can Genomics be the tool to low the rate in which black women are diagnosed with Breast Cancer and extend their lives.

We know that there are 194,280 Americans will be diagnosed with breast cancer this year and 40,610 will die from the disease. 15 percent Black to 7 percent White.

Some guidelines recommend that Cancer stem cells is the fuel that grow Breast Cancer tumor's. Others guidelines recommend that bone mineral density is the fuel that grows tumors.
Chemotherapies do not work against these cells, which is why cancer recurs and spreads. Hybrid Medical Analytics believe that eliminating the cancer stem cells is key to controlling cancer.

21 percent of black women and 15 percent of white women do not receive the minimum expected treatment. Black Women have shorter survival and higher mortality observed for black women
compared to white women.The correlation of lower social class and the lack of Health Care equals less screening, and later stage diagnosis.

Can Genomics be the answer for Black women ? Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment.
Hybrid Medical Analytics Genomics Science looks at 21 genes in a patient’s breast cancer tumor in trials to understand how these genes interact and influence the tumor’s behavior.

Genomics is personalized treatment that will reduce the rate of cancer for Black Women.

Tamoxifen and Raloxifene works the same for Balck and White Women, but to many Black Women say the treatment can be toxic. Black Women state that too much toxicity leads to not taking the treatment.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Analytics CIO Reports Our Sybase Geonomics Glioblastoma Data Mining Shows that the PTPRD Gene shows to be Promising.

2010-02-01T12:24:00.001-08:00

Biotech: Hybrid Medical Analytics CIO Reports that our Sybase Geonomics Glioblastoma Data Mining Shows that the PTPRD Gene shows to be Promising.

Three of every 100,000 Americans have been diagnosed with glioblastoma multiforme ....malignant brain tumors. Most patients with glioblastoma die of the disease within approximately 14 months of diagnosis.

Glioblastoma is not a single disease that appears to be four distinct molecular subtypes Cancer Cell,Investigation of targeted Therapies may improve the near uniformly fatal prognosis of this cancer.

The ability to differentiate Glioblastoma Tumors based on their altered genetic code.Using a cancer's genome to unravel the molecular changes. Comprehensive and coordinated effort to accelerate understanding of how molecular can help extend life
based on cancer through the application of genome analysis technologies and large-scale genome sequencing.

Hybrid Medical analysis Geonomics shows the PTPRD mutations in both the blood and in tumors of a patient with Glioblastoma cancers, can be responsible for an inherited susceptibale to Brain Cancer.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Diagnosed with Breast Cancer should your treatment be Tamoxifen or Chemotherapy ? A Geonomics test will answer this question

2010-01-26T07:27:00.000-08:00

Diagnosed with Breast Cancer should your treatment be Tamoxifen or Chemotherapy ? A Geonomics test will answer this question

Hybrid Medical Analytics asked genetics or geonomics. Genetics is the study of how inherited Cancer traits that are passed from one generation to the next through your genes. New genetics traits appear by way of genetic changes. These traits may be characteristics like eye or hair color.

A predisposition to certain types of diseases can be passed through your genes, such as the BRCA1 and BRCA2 genes which normally help control cell growth.

A person who inherits an altered version of the BRCA1 and-or BRCA2 gene(s) has a higher risk of developing breast and ovarian cancer. If someone in your Family has Breast Cancer you can get a genetic tests for BRCA1 and BRCA2.

When a Breast Cancer Patient is Diagnosed as a high-risk Breast Cancer patient they should get a genomic test. A genomic test looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment.

Hybrid Medical Analytics uses our Electronic Science Notebooks to identify 21 genes in a patient’s breast tumor to understand how these genes interact and influence the tumor’s behavior, contribute to the development of a cancer cell and its progression from a localized cancer to one that grows uncontrolled and metastasizes.

Oncologist can you this information to better understand whether breast cancer patients are likely to benefit from treatments such as tamoxifen or certain chemotherapy regimens, or whether those patients are likely to experience a recurrence of their cancer.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

What would you do if you had a Baby and found a Tumor on his chest and had no health Insurance

2010-01-22T07:26:00.000-08:00

What would you do if you had a Baby and found a Tumor on his chest and had no health Insurance ? Your Baby would most likely have Neuroblastoma Cancer. Once Diagnosed with
Neuroblastoma Cancer the good news is that experimental treatment significantly improved progression-free survival in patients with neuroblastoma at high risk for recurrence.

Neuroblastoma Cancer develop from cells of the sympathetic nervous system, A Clinical trial that is showing promise is a study that treatment of high-risk neuroblastoma of the ch14.18 monoclonal antibody. 90% of kids in this study live to 5 years.
The Goal here is to stimulate glycolipid (GD2) force the immune system responded.

The trial used standard therapy, which includes intensive chemotherapy, surgery, and a stem cell transplant, followed by radiation therapy.

Hybrid Medical Analytics is a leader in stem cell R&D with our Lab eNotebook.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hong Kong: Hybrid Medical Analytics Algorithm - Drugs Treatments that kill Breast Cancer Stem Cells has shown Promise

2010-01-14T07:44:00.000-08:00

Hong Kong: Hybrid Medical Analytics Algorithm - Drugs Treatments
that kill Breast Cancer Stem Cells has shown Promise

Hybrid Medical Research Base Protocol stem cell transplantation for the treatment of advanced and early-stage breast cancer is shown promise when adding Collaborative Technology Mythologies to the process. The treatment of high-dose chemotherapy with transplantation as apposed to treatment with more standard doses of chemotherapy.

When pointing Hybrid Medical Algorithm to breast cancer patients with four or more lymph nodes positive for cancer and who are at high risk of recurrence of Breast Cancer have received the best results. These Women are treated with high-dose chemotherapy with granulocyte colony stimulating factor (G-CSF) to stimulate white blood cell production.

Our Oncologist Clients are driven by the fact that more than 75 percent of the women who had heard of high-dose chemotherapy with transplant said they would very likely consider this form of treatment if faced with a decision about breast cancer treatment.

Hybrid Medical CIO Reports that Breast Cancer Stem Cells Treatments are here to stay.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hereditary Cancer Syndromes BRCA1 shows Concerns about Whole Body Scans in Breast Cancer Patients Kids

2010-01-07T08:29:00.000-08:00

Hybrid Medical Analytics CIO Reports that Hereditary Cancer Syndromes BRCA1 shows Concerns about Whole Body Scans in Breast Cancer Patients Kids.

The names BRCA1 and BRCA2 stand for breast cancer susceptibility
gene 1 and breast cancer susceptibility gene 2.

Five percent of the Uninsured Americans is Radiosensitive. One percent of the five percent carry the BRCA1 and BRCA2 breast cancer genes.

Scanning technology reveals detailed images of breasts, genitalia,
surgical implantsa. In less-developed nation might adopt backscatter scanning technology and fail to keep their scanners calibrated.

Test for BRCA1 and BRCA2 mutations look for
changes in BRCA1 and BRCA2 DNA and changes
in the proteins produced by these genes.
Hybrid Medical Analytics Recommend that if you have family member with a history of breast and/or ovarian cancer,ask your Physician to test for BRAC1 and BrcA2.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Analytics CIO Reports 5% of The Uninsured Men have Risk of Familial Cancer, or Inherited, Testicular Germ-Cell Cancer.

2009-12-22T07:52:00.000-08:00

Hybrid Medical Analytics CIO Reports 5% of the uninsured men have risk of Familial Cancer, or inherited, testicular germ-cell cancer.
Hybrid Medical Analytics believe that multiple genes with weaker individual effects--acting together--probably influence an individual's risk of familial testicular cancer.
90% of the 8,400 new cases of testicular cancer diagnosed this year is Germ Cancer.
The cyclic AMP pathway is the Key to treating Testicular Cancer.There are
Ready Available Drugs on the market that target the PDE11A Gene.
If you have strong candidate in your family for this gene, mutation
and trait the Healthcare Bill in the 111th Congress is will extend the life of Americans with Familial Testicular Germ Cell कैंसर

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Analytics CIO Says that Drugs that kill cancer stem cells has a 72% rate of having Breast Cancer to not reoccur

2009-12-04T20:43:00.000-08:00

Hybrid Medical Analytics CIO Says that Drugs that kill cancer stem cells has a 72% rate of having Breast Cancer to not reoccur.

Cancers generally comes From Tissue Stem Or Progenitor Cells
The Gene Dlg7 has a role in stem cell survival, maintaining
stem cell properties, and in carcinogenesis.

Cancer cells are heterogeneous, and only rare cancer
stem cells have the ability to proliferate extensively
and form new tumors.

Cancer Stem Cells is how New Tumors are created.
Mammary stem cell allows self-renewal pathways.
How this works is that Drugs that kills cancer stem cells forces
tumor to lose its ability to regenerate and create new cancer cells.The
Tumor degenerates, and then you the patients is cured.

If you are Diagnosed with Breast Cancer make sure you ask
you oncologist if the Treatment that they are prescribing kills
Stem Cell.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical CIO Reports-38% Increase Palliative Care for Cervical Cancer Patients Sexual Functioning

2009-11-21T08:35:00.000-08:00

Palliative Care include the physical, social, psychological, and spiritual
aspects of coping with cancer over the entire continuum of cancer care.

Hybrid Medical Analytics are Partners in Palliative Care. Hybrid Medical objectives is to share strategies, avoiding duplication and identifying knowledge gaps for the 9.6 million Americans who have experienced and survived cancer.

Globally, there are 24.5 million people living with a history of cancer
and 10 million cancer survivors in the United States. That has to deal
with cancer symptoms, including weight loss or gain, fatigue, hot flashes,
pain, nausea, and vomiting.

Hybrid Medical main focus is the surveillance of Cervical Cancer.
Our Analytic Team of Researchers hope to develop culturally sensitive,
short-term interventions to improve sexual functioning and overall quality of life. That identify factors that may predict better sexual function outcomes in patients treated for cervical cancer.

We are sharing information in the area of of sexual functioning (desire, arousal, orgasmic capacity, dyspareunia, and sexual satisfaction) over the course of treatment. Early follow-up in patients with local and locally advanced cervical cancer. This Research and Analytics will allow Patients and their Families Understand and Manage Cervical Cancer.
Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Experts that Issued a Call To Reconsider Screening For Breast Cancer

2009-11-17T06:07:00.000-08:00

Breast Cancer Patients without Health Insurance often have to rely on Cancer Trials. At Hybrid Medical Analytics Business Intelligence show
Newly Diagnosed Metastatic Breast Cancer Patients getting Taxanes treatment did 8% better than Breast Cancer Patients receiving Anthracyclines for their treatment. 15 percent of Black Females who get cancer to 7 percent of white Females who get cancer are face with having to have clinical trials because their cancer are diagnosed in
the Metastatic Stage.

For this reason Black Female should not follow this week report
from Experts that Issued a Call To Reconsider Screening For Breast Cancer.

This is not something women of color should follow.

Hybrid Medical Analytics Inc Business Intelligence:

15 % of Black African women is diagnosed with breast cancer to
7 % of white women. One of the great drugs that is use if you are in a high risk group for Breast Cancer is called Nolvadex. Black women, as a population, have higher rates for stroke and pulmonary embolism and lower rates of endometrial cancer, all of which may be increased by Nolvadex.

Percentage of breast cancer patients diagnosed with metastatic disease
(cancer that had spread):

White – 7%

Indian – 11%

Pakistani – 17%

Bangladeshi – 13% (not statistically significant because there were so few Bangladeshi women in this sample)

Black Caribbean – 11%

Black African – 15%

Chinese – 10%

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Analytics CIO Reports - Excessive thirst in kids 30 months & younger can be Diabetes Insipidus

2009-11-14T06:32:00.000-08:00

Hybrid Medical Analytics CIO Reports - Excessive thirst in kids 30 months
& younger can be Diabetes Insipidus Childhood Langerhans Cell Histiocytosis.

The outcome for children with Childhood Langerhans Cell Histiocytosis involving high-risk organs (spleen, liver, bone marrow, and lung) has 68% Rate of Improvement. The outcome for children with LCH involving low-risk organs (skin, bones, lymph nodes, and pituitary gland) has always been excellent, but the major challenge is to reduce the relatively high incidence (20%–30%) of recurrent lesions.

Hybrid Medical incidence of Childhood Langerhans Cell Histiocytosis occurs in less than 1% of the Population with the median age of 30 months.

Hybrid Medical Childhood Langerhans Cell Histiocytosis diabetes insipidus involves orbital, mastoid, and temporal bonesand a increased frequency
of anterior pituitary hormone deficiencies and neurologic problems.

The Langerhans cell (LC) originates from bone marrow stem cells as an immature dendritic cell, which can then develop into the LC under the influence of several cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF alpha).These immature cells are found in the skin, lymph nodes,
spleen, bone marrow, and lungs.

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Analytics Neuroblastoma is the Cancer that will benefit the most from the Passage of the Health Care Bill

2009-11-08T11:14:00.000-08:00

8% of 30 Million Uninsured has Familial Cancer 1% of the 8% Kids has the
ALK Gene on Chromosome2 that results in Neuroblastoma Cancer.

Hybrid Medical Analytics Business Intelligence CIO Reports - 50% of the Moms with the Gene MYCN or CD44 Kids will have Neuroblastoma Cancer.

The way Moms can recognized Neuroblastoma is a Abdominal Mass.
The symptoms in high-risk patients are due to this tumor mass or bone pain from the cancer metastases.

Extensive bone marrow metastasis may result in pancytopenia. Abdominal distention with respiratory compromise due to massive liver metastases may occur in infants.Because they originate in paraspinal ganglia, neuroblastomas may invade through neural foramina and compress the spinal cord extradurally, causing paralysis.

The survival rate is twice as high if diagnosed in infants less that one years old.

For mothers that do not have Health Insurance and is not getting prenatal care accounts for 70% of the Cases diagnosed in infants greater than one years old.

Based on Hybrid Medical Analytics Neuroblastoma is the Cancer that will benefit the most from the Passage of the Health Care Bill.

Breast cancer
Endocrine system cancer
Gastrointestinal cancer
Genitourinary cancer
Gynaecological cancer
Haematological cancer
Head and neck cancer
Neurooncology
Paediatric oncology
Thoracic oncology
Sarcoma
Skin cancer
Epidemiology, cancer prevention, and cancer control
Supportive care
Imaging
Health-care systems

52% of all Parenchymal Brain Tumor cases are Glioblastoma Multiforme

2009-10-29T15:38:00.000-07:00

TX MedCenter @HybridMedical Business Intelligence Algorithm & Decision Theory shows Temozolomide & Radiation for Glioblastoma Multiforme Extends Life.

Glioblastoma multiforme, the most common and most aggressive form of brain cancer in adults, Glioblastoma is considered incurable. 52% of all parenchymal brain tumor cases are Glioblastoma multiforme.
If you are Diagnosed with Glioblastoma your choice is to have Radiation treatments or have Radiation with Adding Temozolomide. Oncology & Hybrid Medical Research shows after two years, 26.5 percent of patients in the radiation-plus-temozolomide were alive, compared with 10.4 percent of those who received radiation only. Temodar is the Generic for Temozolomide

Hybrid Medical Research are Leaders in the following areas:

Breast cancer
Endocrine system cancer
Gastrointestinal cancer
Genitourinary cancer
Gynaecological cancer
Haematological cancer
Head and neck cancer
Neurooncology
Paediatric oncology
Thoracic oncology
Sarcoma
Skin cancer
Epidemiology, cancer prevention, and cancer control
Supportive care
Imaging
Health-care systems